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Abstract 
In adults, precisely regulated gene expression results in strict control of cell 
proliferation required for healthy tissues. Abnormal gene expression, on the other hand, 
can result in uncontrolled cell proliferation and tumor formation. Gene expression largely 
depends on changes to chromatin structure; it is remodeled in response to epigenetic 
stimuli to accommodate transcriptional activation and/or repression. Chromatin 
remodeling, therefore, is very broadly fundamental to normal and aberrant cellular 
function. Here, my research has focused on a key epigenetic effector that facilitates gene 
activation, called Pygopus 2 (Pygo2). Pygo2 functions primarily to link histone 
acetylation to active gene expression, by bridging transcription factors and modified 
histone proteins at gene promoters to histone acetyltransferases.  
In this thesis, I first examined the role of Pygo2 in the canonical Wnt signaling 
pathway and found that Pygo2 is transiently and specifically acetylated when bound to 
the activated -catenin complex. Acetylation of Pygo2 correlated with a displacement of 
nuclear Pygo2 to the cytoplasm, suggesting that acetylation of Pygo2 may control the 
recycling of -catenin complexes, following target gene activation. Upon examination of 
the broader role of Pygo2 beyond Wnt signalling, I found that it promotes ribosomal 
(r)RNA transcription within the nucleolus. In this context, Pygo2 was required for histone 
H4 acetylation at the rDNA promoter, suggesting a novel involvement of Pygo2 in rRNA 
transcription. Finally, using a whole genome approach, I discovered that Pygo2 acts as a 
pleiotropic chromatin effector, revealing a function for Pygo2 in gene expression required 
for segregation and bi-orientation of chromosomes during mitosis. Further analysis 
identified an interaction between Pygo2 and c-myc oncoprotein, suggesting that the 
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chromatin effector Pygo2 may cooperate with c-myc, directing the expression of growth 
and division genes. 
Taken together, my findings suggest that in association with other important 
regulators of growth in cancer, Pygo2 facilitates gene expression by interpreting and 
relaying positive epigenetic marks on histones, which is essential to promote the 
expression of proliferation-related transcriptional programs.  
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Chapter 1: Introduction  
 2 
 
1.1 Foreword: The abnormal growth of cancer cells 
 
 The idea of the “hallmarks of cancer” was first introduced in 2000 by Douglas 
Hanahan and Robert Weinberg, in which they described six defining characteristics of a 
cancer: Activation of growth signalling, inactivation of growth suppression, inactivation 
of cell death mechanisms, acquisition of immortality, activation of angiogenesis, 
acquisition of invasion and metastasis (Hanahan & Weinburg, 2000). In 2011, two new 
defining characteristics were added: reprogramming of energy metabolism and evasion of 
the immune system (Hanahan & Weinberg, 2011).  
Cancer is a multistep process that occurs over many years arising from three to six 
driver mutations affecting gene function (Vogelstein & Kinzler, 1993), with  additional 
mutation(s) leading to an increased detrimental or aggressive phenotype. Whole genome 
sequencing has revealed that cancers can exhibit thousands of mutations, consisting 
mostly of  “passenger” mutations that do not directly confer a growth advantage, while a 
subset of mutations occurring in more than 120 genes were likely responsible for driving 
cancer development (Greenman et al, 2007). More recently, the number of identified 
driver mutations has increased to over 140 genes and as few as two to eight of these 
“driver” mutations are sufficient to initiate and promote tumorigenesis, consistent with 
Vogelstein and Kinzler’s original theory in 1993 (reviewed in: Vogelstein et al., 2013).  
Somatic mutations occur either from environmental agents or from errors 
associated with DNA replication, while hereditary germline mutations result in the 
predisposition of an individual to cancer and likely result in a more rapid accumulation of 
mutations (reviewed in Brücher and Jamall, 2016). With the accumulation of mutations 
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there is an increased likelihood that driver mutations will occur in genes whose functions 
are involved in one or more of the “hallmarks” described above. Driver mutations likely 
directly affect the function of master regulator proteins (Califano & Alvarez, 2016), 
which play many roles controlling the expression of regulatory circuits necessary and 
required for transformation. For example, the proto-oncogene c-myc functions as a 
master regulator protein by controlling a growth promoting transcriptional program.   
Tumor cell growth is complex and driven by the acquisition of mutations that 
confer selective growth advantages; the more driving mutations acquired, the more 
aggressive the tumor becomes. Cancer cells “evolve” into more aggressive groups of 
cells that make up tumors. Tumors start with one cell; the cell grows and divides to form 
a clonal population. The more cells existing in the tumor the higher chance there is that a 
second cell that acquires an additional mutation giving selective advantages over the first 
clonal population. It is here where it is possible for a cell from the first population to 
evolve to produce a new subset of the previous tumor, hence with each new driving 
mutation, a tumor will eventually become a heterogeneous collection of smaller tumors, 
thereby posing a big challenge for therapy (reviewed in: McGranahan and Swanton, 
2015).  
Cancer cell growth is therefore dynamic and is largely dependent on driver 
mutations affecting gene expression. With gene expression partly depending on 
transcription, it is not surprising that transcription is often aberrantly regulated in cancer. 
In the following section, I will take a closer look at transcription, how it is regulated and 
how its’ deregulation is associated with cancer.   
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1.2 Transcriptional regulation and chromatin remodeling 
 
The central dogma of genes being transcribed into RNA, which is translated into 
protein, is a powerful but simplistic model of gene expression. Gene expression is a far 
more complex process that can be viewed as a cellular response to a variety of intrinsic 
and extrinsic stimuli required for every cell to adapt to its local environment. If the 
transcription of genes involved in cell growth is not tightly controlled or regulated the 
result might be a constant growth or cancer phenotype.  
Transcription is regulated primarily by protein factors that are responsible for 
controlling two broad processes. First, different sets of DNA binding proteins and 
transcription-associated factors direct the core transcriptional components to specific 
DNA sequences that reside within close proximity to the sequence to be transcribed. 
Second, due to the compact packaging of DNA into chromatin, chromatin associated 
factors are required to influence an amenable DNA structure to allow transcriptional 
components access to the DNA sequences. While this is a very simplistic view, the 
complexity of transcription depends on a several sequential protein-protein, protein-DNA 
and RNA interactions with proteins and DNA. I will begin by taking a closer look at 
transcriptional regulation and then later look at gene structure and chromatin 
organization, which is fundamental to transcriptional regulation. 
1.2.1 Transcription 
 To simplify, I will give a brief overview regarding the regulation of transcription 
apart from the surrounding chromatin, which I will discuss in a later section. Thousands 
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of RNA and protein-coding genes in the human genome are controlled by transcription 
associated protein complexes that associate with DNA sequences as well as the 
machinery responsible for transcription. Transcription itself can be broken down into 
three distinct phases, including initiation, elongation and termination (Figure 1.1; for 
description see below).  
Transcription factors are typically regulated by upstream cell signalling cascades 
that promote or inhibit various protein-protein interactions and post-translational 
modifications, switching them to a favorable conformation that is amenable for their 
association with DNA. Initially, pioneer transcription factors bind directly to DNA and 
are required to recruit larger protein complexes to modify and physically bend the DNA, 
required to activate transcription (Zaret & Carroll, 2011).  
 Activated transcription factors bind to specific DNA sequences at genetic control 
elements known as enhancers and promoters, which lie upstream of each gene. Enhancer 
sequences are gene regulatory elements that are positioned hundreds to thousands of 
bases upstream, whereas promoter sequences reside in close proximity to the 
transcriptional start site (TSS) for each particular gene. Enhancer-promoter looping and 
interaction is mediated by intricate protein-protein, protein-DNA and protein-RNA 
interactions among transcription factors, transcription associated proteins and RNAs, as 
well as the surrounding chromatin. Enhancer-promoter looping is required for the 
targeted recruitment of the basal transcription machinery and RNA polymerase to 
promoter sequences adjacent to TSS to initiate gene transcription (Reviewed in: Krivega 
and Dean, 2012; Vernimmen and Bickmore, 2015).        
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Figure 1.1. Transcription in eukaryotes. Transcription can be broken down into three 
distinct phases, initiation, elongation and termination. Initiation of transcription requires 
the sequence specific binding of transcription factors to both enhancer and promoter 
elements required for the recruitment of RNA polymerase II (Pol II). Transcriptional 
elongation resulting in the formation of a nascent mRNA requires the association of 
elongation factors, such as P-TEFb with Pol II. Several types of mechanisms can mediate 
transcriptional termination resulting in release of Pol II and the newly synthesized 
mRNA, including: PAS, R-loop structures and heterochromatin. 
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The basal transcription machinery consisting of TFIIB, TFIID, TFIIE, TFIIF and 
TFIIH complexes, along with RNA polymerase, make up a larger complex known as the 
preinitiation complex (PIC) that is associated with activated gene promoters. The TFIID 
complex contains the classical TATA binding protein (TBP) and TBP associated proteins 
that associate with specific TATA binding sequences approximately 30 bases upstream 
from the TSS and is required for transcription (Dynlacht et al, 1991). The basal 
transcription machinery binds to active promoters through association with the 
transcription associated proteins and is required to recruit RNA polymerases to initiate 
transcription. In eukaryotes, there are three RNA polymerase (Pol) enzymes capable of 
transcribing DNA sequence to produce RNA. RNA Pol I is required for transcription and 
production of ribosomal RNAs, RNA Pol III is required for transcription of transfer (t) 
RNAs, whereas, RNA Pol II is required for transcription of all other RNA species, 
including mRNAs and non-coding RNAs. Transcriptional initiation is achieved after 
assembly and activation of the PIC, whereby RNA polymerase is activated in the 
presence of ATP and then proceeds to melt or separate the double stranded DNA at the 
core through its DNA helicase activity, thereby forming a transcription “bubble”. It is 
here where the surrounding DNA is unwound and decoded by RNA polymerase as RNA 
synthesis proceeds (reviewed in: Sainsbury et al., 2015; Sikorski and Buratowski, 2009)   
During transcriptional elongation, RNA polymerase association with the Positive 
Transcription Elongation Factor b (P-TEFb) is required for the formation of nascent RNA 
(Zhou et al, 2012). RNA polymerase slows as it reaches specific DNA sequences known 
as transcriptional past the polyadenylation sites (PAS), which act a signals for 
transcriptional termination. PAS sites along with other termination mechanisms, such as 
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the R-loop structures formed by the RNA transcript and the DNA, the RNA polymerase 
association with termination factors and the chromatin dependent mechanisms, are 
required for termination of transcription, release of the nascent RNA and dissociation of 
the complex from the DNA (reviewed in: Proudfoot, 2016).  
 Transcription is, therefore, a coordinated process executed by many factors 
required for the recruitment and activation of the RNA polymerase. The tight packaging 
of DNA into chromosomes adds further complexity to this process, which must be 
overcome to facilitate RNA production. In the following section, I will focus on the 
organization of DNA into chromatin and how it is modified to facilitate transcription. 
 
1.2.2 Chromatin structure 
 Due to physical space limitations within a eukaryotic cell, DNA is very efficiently 
packaged into chromatin, which consists of linear double stranded DNA molecules that 
are wrapped tightly around groups of histone proteins, making up the basic units known 
as nucleosomes. Complexes of histone octamers containing the core histone proteins 
H2A, H2B, H3 and H4 make up the foundation of the nucleosome and are arranged in 
such a way that the positively charged amino (N) -terminal tails of the histone proteins 
are free to interact with the negatively charged DNA. Each nucleosome consists of 146 
base pairs of DNA that are wrapped around a histone octamer complex 1.65 times in a 
left-handed superhelix, resembling beads on a string (Luger et al, 1997). Histone H1 
proteins interact with each nucleosome and are required to package the nuclesosomes into 
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higher order structures that make up the 30nm chromatin fibers of each chromosome 
(Reviewed in: Felsenfeld and Groudine, 2003; Grigoryev and Woodcock, 2012).  
This highly ordered, tightly packaged structure represents a major hurdle, which 
must be overcome to facilitate transcriptional initiation and gene expression. Therefore, 
highly condensed chromatin or heterochromatin is modified in such a way that makes it 
accessible to transcription-associated proteins. This was first described based on the 
sensitivity of chromosomal DNA to nuclease digestion, whereby a DNA cutting enzyme 
could gain access to the chromosomal DNA and cut it to produce smaller fragments 
(Weisbrod, 1982). It was therefore hypothesized that the resulting open chromatin or 
euchromatin was a product of modified DNA or histone proteins and was likely required 
for transcription to take place. We now know that the interactions of DNA and histone 
proteins are highly dynamic and depend on chemical modifications to histones required 
to open or close chromatin structure. In the following section, I will take a closer look at 
the types of chromatin remodeling and focus on the chemical post-translational 
modifications that take place on histone proteins required to facilitate gene expression.   
1.2.2.1 Chromatin remodeling  
 The structure of chromatin is highly dynamic to facilitate events required for 
major cellular functions, such as replication, transcription, DNA repair and cell division. 
For example, cell division requires DNA to be highly condensed and tightly associated 
with histones, on the other hand, transcription requires the DNA to be “relaxed” or less 
tightly associated with nucleosomes. Therefore, chromatin structure is malleable, and 
constantly being “remodeled” or changed.  
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As mentioned above, one major feature of chromatin remodeling is to facilitate 
access of transcription-associated protein complexes. Chromatin remodeling occurs 
primarily through the actions of enzymatic chromatin remodeling proteins that can either 
add or take away covalent chemical modifications to both DNA and histone proteins, 
resulting in either open (euchromatin) or closed (heterochromatin) chromatin structure. It 
is well known that chromatin remodeling is not limited to transcription and is required for 
many cellular processes, such as DNA damage repair (Price & D’Andrea, 2013) and 
DNA replication (Alabert & Groth, 2012). In the following sections, I will explore 
chromatin remodeling by first briefly touching on DNA methylation. Next, I will focus 
on two major classes of proteins: the ATP dependent chromatin remodelers and the post-
translational chromatin remodelers. 
1.2.2.2 DNA methylation  
 The first group of chromatin remodelers that I will briefly discuss are the DNA 
methyltransferases (DNMTs), which catalyze the covalent attachment of a single methyl 
group directly to the DNA, thereby generating 5-methylcytosine residues at cytosine-
guanosine dinucleotide (CpG) sequences ( Goll & Bestor, 2005). Following methylation 
of CpG dinucleotides by DNMTs, complexes of methyl-CpG binding proteins mediate 
the repression of gene expression by recruiting other chromatin modifiers, resulting in 
repressive histone modifications. DNA methylation is typically associated with long term 
repression of chromatin and plays important roles in both normal development and 
cancer, such as in X chromosome inactivation and the repression of tumor suppressor 
expression, respectively (reviewed in: Cedar & Bergman, 2009; Klose & Bird, 2006).  
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1.2.2.3 ATP-dependent chromatin remodeling  
The group of chromatin remodelers that utilize energy generated from the 
hydrolysis of ATP, are therefore dubbed the ATP-dependent chromatin remodelers. The 
yeast Switch/Sucrose non-fermentable (SWI/SNF) proteins were the first ATP-dependent 
chromatin remodelers identified (Côté et al, 1994). SWI/SNF homologues in humans are 
called Brg/Brahma associated factors (BAF), however, ATP-dependent chromatin 
remodeling is often referred to as SWI/SNF chromatin remodeling. ATP-dependent 
chromatin remodeling involves the displacement or mobilization of nucleosomes with 
respect to the DNA, resulting in rapid large scale changes to chromatin structure 
(Hargreaves & Crabtree, 2011; Narlikar et al, 2013; Clapier & Cairns, 2009) . The 
mechanism of ATP-dependent chromatin remodeling relies on the DNA translocase 
activity possessed by ATP-dependent chromatin remodelers. These remodelers disrupt 
the DNA-histone interactions and move the DNA with respect to the histones, thereby 
resulting in nucleosome displacement or sliding (Saha et al, 2002) required for  
transcription, DNA replication and DNA damage repair. In the following section, I will 
look at chromatin remodeling that occurs by the direct chemical modification of histone 
proteins that result in changes to chromatin structure.  
1.2.2.4 Chromatin remodeling by the post-translational modification of histones 
The second group of chromatin remodelers that modify chromatin generally do 
not require ATP for energy and contain catalytic regions within their sequences, which 
promote covalent post-translational modification of the N-terminal histone tails 
protruding from nucleosomes. This type of chromatin remodeling exists in an 
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equilibrium, whereby covalent modifications are added or “written” and taken away or 
“erased” from the histones tails. The families of enzymes that “write” or “erase” histone 
modifications, are classified primarily on the chemical modification they add and 
remove, for example: acetylation, methylation, phosphorylation, ubiquitination and 
sumoylation. In this thesis, I will focus primarily on two modifications relevant to my 
work, which are histone acetylation and histone methylation.  
1.2.2.5 Histone acetylation  
 Acetylation involves the enzymatic transfer of acetyl groups from the donor 
molecule acetyl-CoA to the positively charged lysine residues of target proteins. Lysine 
acetylation is not limited to histone proteins and is very important in the broad regulation 
of protein function (Close et al, 2010). Nonetheless, histone acetylation is probably one 
of the most well studied examples of histone modifications and in general is strongly 
correlated with the formation of an open chromatin structure required for transcriptional 
activation. The mechanism by which histone acetylation affects chromatin structure is 
relatively simple: Acetylation reversibly modifies the positive charge of the amino (N) 
terminal histone tails existing on the outer surface of the nucleosome into a neutral 
charge. This charge switch is sufficient to repel the negatively charged phosphodiester 
DNA backbone away from the histones resulting in an open chromatin structure 
(Grunstein, 1997).  
Like all acetyltransferases, families of histone Acetyl Transferase (HAT) proteins 
possess enzymatic domains responsible for the catalytic transfer of acetyl groups to target 
proteins, in particular, histones, as their name implies. Nuclear HATs all play major roles 
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in transcription and can be divided into several different subfamilies including the Cyclic 
AMP Binding Protein Binding Protein (CBP)/p300, the General Control non-
derepressible (GCN5)-related N-acetyltransferase and the MOZ/Ybf2/Sas2/3/Tip60 
(MYST) subfamilies (reviewed in: Kouzarides, 2007; Tessarz and Kouzarides, 2014).  
With respect to chromatin remodelling, each HAT subfamily targets unique lysine 
residues on N-terminal histone tails for acetylation. For example, in mouse embryonic 
fibroblast cells CBP/p300 targets histone H3 Lysine 18 (H3K18) and Lysine 27 (H3K27) 
acetylation, while GCN5 and its related subfamily member, p300/CBP Associated Factor 
(PCAF) target histone H3 lysine 9 for acetylation (Jin et al, 2011). It is also likely that 
multiple HAT complexes are recruited to transcriptional start sites of active genes given 
that acetylation of histones at different lysine residues tend to co-localize at specific sites 
in the genome and correlate with transcriptional activation (Wang et al, 2008). 
Histone deacetylase (HDAC) proteins on the other hand, shift chromatin structure 
from an open state to a closed state. The enzymatic activity of HDACs results in the 
hydrolysis of acetylated lysine residues, thereby releasing the acetyl group as a single 
molecule of acetate (Lombardi et al, 2011). Protein deacetylases exist as two broad 
families; the first classical family comprising the Zn2+ dependent HDACs share 
homology to the yeast protein Rpd3, while the second family comprising the NAH+ 
dependent Sirtuins (SIRT) share homology to the yeast protein Sir2 (reviewed in: 
Haberland et al., 2009; Roth and Chen, 2014). While both families of deacetylases 
display a broad range of substrates, both play roles in chromatin remodelling and largely 
function as transcriptional co-repressors. 
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1.2.2.6 Histone methylation  
 Similar to acetylation, methylation requires specialized enzymes required for the 
post-translational addition of methyl groups from the donor molecule S-
adenosylmethionine to positively charged lysine and arginine residues of target proteins. 
In contrast to acetylation by which only one acetyl group is added to one amino acid, 
methylation occurs at different levels through the addition of one, two or three methyl 
groups per amino acid and does not change the overall charge of the residue. It is 
therefore not likely that histone methylation significantly changes chromatin structure in 
the same way acetylation does, and likely serves to promote or take away docking sites 
for transcriptional regulatory proteins (Tessarz & Kouzarides, 2014; Greer & Shi, 2012).  
Three families of methyltransferases have been identified and are classified based 
on their ability to methylate lysine and arginine residues. The lysine methyltransferases 
(KMTs): Suv, Enhancer of Zeste, Trithorax (SET) group, which share a conserved SET 
domain, and the Disruptor of Telomeric silencing (DOT1) group both target Lysine 
residues for methylation, whereas the Protein arginine N-methyltransferase (PRMT) 
group targets arginine residues for methylation (reviewed in: Bannister and Kouzarides, 
2011; Greer and Shi, 2012).  
Even though methylation is an important post-translational modification 
regulating non-histone protein function (Hamamoto et al, 2015), the context dependent 
methylation of histones can be associated with either activation or repression of 
transcription. For example, trimethylation of histone H3 at lysine 4 (H3K4me3) is 
associated with transcriptional activation (Santos-Rosa et al, 2002) and trimethylation of 
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histone H3 at lysine 27 (H3K27me3) is associated with the recruitment of Polycomb-
group transcriptional repressors (Cao et al, 2002).  
Early studies examining histone methylation suggested that it was an irreversible 
process (Byvoet et al, 1972), however we now know protein methylation is indeed a 
reversible process and is carried out by specific families of histone methylases and 
demethylases. The revisited concept that histone methylation is a reversible process 
(Bannister et al, 2002) prompted the search for enzymes capable of demethylating 
histones, which led to the functional identification of one of the first histone 
demethylases, Lysine Specific Demethylase 1 (LSD1; Shi et al, 2004). However, LSD1 
was only capable of demethylating monomethylated and dimethylated H3K4, therefore 
suggesting the existence of further demethylases capable of demethylating trimethylated 
lysines. It was later found that the Jumonji C (JmjC) domain containing histone 
demethylase 1 (JHDM1) was capable of demethylating H3K36 and hence represented a 
second class of histone demethylases (Tsukada et al, 2006). Finally, through a candidate 
approach, a larger family of more than thirty JmjC domain containing proteins were 
identified and shown to have broad histone demethylase activity, including the 
demethylation of trimethylated Lysines (Dimitrova et al, 2015).   
1.2.3 Interpreting the histone code  
Thus far, I have discussed mechanisms that cells have evolved to open and close 
chromatin to allow or deny access to DNA. From a global perspective, at any point in 
time, chromatin is a complex and dynamic mix of open and closed chromatin, which 
reflects the ongoing state of histone modifier activity. histone modifiers that add chemical 
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components have been called “writers” and those that remove components, “erasers”. 
The different combinations of modifications make up the “histone code”, thereby 
providing detailed instructions that can be interpreted by the histone “readers”, 
functioning as effector molecules involved in the positive or negative regulation of 
transcription (Figure 1.2). 
As briefly mentioned above, histone methylation in contrast to histone acetylation, is not 
directly involved in promoting open chromatin structure. On the other hand, histone 
methylation together with acetylation can directly affect the interaction of numerous 
protein families involved in transcriptional regulation. Given the basic nature of the 
histone tails that protrude from each nucleosome, various combinations of histone 
modifications provided by the histone writers and erasers that make up the code are 
possible. 
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Figure 1.2. Histone code readers, writers and erasers. Reversible modifications made 
to histone proteins by epigenetic “writers” and “erasers” result in changes to nucleosomal 
structure resulting in the recruitment of factors or “readers”, which directly associate with 
modified histones. Histone “readers” are involved in promoting several processes, such 
as DNA replication and repair, as well as transcription. Adapted by permission from 
Macmillan Publishers Ltd: [Nature Reviews Drug Discovery] (Falkenberg & Johnstone, 
2014), copyright (2014). 
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1.2.3.1 Histone code readers 
Post-translational modification of histones through the work of histone writers 
and erasers provide specific instructions at discrete sites of chromatin in the genome. 
However, these instructions must be interpreted by unique sets of proteins to elicit a 
cellular response. Instructions provided by the histone code induce the recruitment of a 
variety of protein families of code readers, capable of binding to specific histone 
modifications. The function of histone code readers is to provide effector functions that 
either open or close chromatin, as well as promote or inhibit recruitment of 
transcriptional activators and repressors.  
To date, several protein families with highly conserved interaction domains have 
been identified, possessing the ability to interact directly with post-translationally 
modified residues of histone proteins. In this section, I will take a closer look at the 
different domains of chromatin reading proteins that interact directly with post-
translationally modified histones, such as acetylated and methylated residues. 
1.2.3.2 Readers of acetylated histones  
The existence of histone code readers was unknown until the end of the 
millennium, when it was shown that the bromodomain of the acetyltransferase co-
activator, PCAF, could specifically interact with acetylated lysine residues (Dhalluin et 
al, 1999). At this point in time, the importance of the bromodomain was unknown and 
had already been described as a conserved domain in a number of proteins, most of which 
had function in transcriptional activation (Haynes et al, 1992). Therefore, the landmark 
paper published by the Zhou lab in 1999 (Dhalluin et al, 1999) represented a huge leap 
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forward with respect to studies describing chromatin remodelling. To date, only a few 
protein domains have been identified to interact with acetylated Lysine residues including 
the bromodomain, the double plant homeodomain and the double pleckstrin homology 
domain, with the bromodomain being the most well described (Musselman et al, 2012).  
The bromodomain containing proteins, comprising the largest group of acetyl-
lysine readers, have been loosely classified into eight subfamilies (reviewed in: 
Filippakopoulos and Knapp, 2012). Class I and III subfamilies function as nuclear HATs 
and include the proteins: PCAF, GCN5, CBP and p300. Class II subfamilies represent the 
Bromodomain and Extraterminal (BET) domain proteins and often contain two adjacent 
bromodomains, such as BRD4. Class IV, V and VII families function as transcriptional 
regulators such as BRD1 and TATA binding proteins. Finally, Class VI and VIII 
bromodomain containing proteins include methyltansferases as well as SWI/SNF ATP-
dependent chromatin remodellers. Therefore, bromodomain containing proteins 
encompass a diverse family of acetylated Lysine readers, most of which have some 
ascribed role in transcriptional activation, which is not surprising given the strong 
correlation between histone acetylation and transcriptional activation. 
1.2.3.3 Readers of methylated lysines 
Since both lysine and arginine can be modified with multiple methyl groups, 
histone methylation represents a multifaceted post-translational modification, that can be 
related to both transcriptional activation or repression. In brief, much less is known about 
arginine methylation. The most well known methyl arginine readers are the Tudor 
domain containing proteins, which represent a relatively poorly characterised group of 
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approximately thirty proteins that show some promiscuity towards methylated lysine 
residues. Tudor domain containing proteins have functions in protein-protein interaction 
as well as RNA-protein interactions and may play roles in both transcription and RNA 
splicing (reviewed in: Gayatri and Bedford, 2014).  
Methylation readers are broadly categorized into three families based on the 
structure of the functional binding domain. The chromodomain, tudor domain, PWWP 
and the Malignant Brain Tumor (MBT) families with a barrel-like domain, WD40 
proteins with a propeller-like domain and the plant homeodomain (PHD) proteins contain 
a zinc finger-like domain (reviewed in: Gayatri and Bedford, 2014). Similarly, all contain 
a methylated lysine binding pocket, which is dependent on the presence of 2-4 aromatic 
amino acids that form an aromatic cage-like structure.   
There are many families of proteins that bind directly to methylated lysines, some 
of which recruit transcriptional repressors and some of which recruit transcriptional co-
activators. For example, H3K9 and H3K27 acetylation is generally associated with 
transcriptional activation, H3K9me3 and H3K27me3 represent repressive histone marks 
that recruit the chromodomain proteins Heterochromatin Protein 1 (HP1) and the 
polycomb repressor complex which function as transcriptional co-repressors that silence 
gene expression (Cao et al, 2002; Bannister et al, 2001). Some PHD-containing proteins 
bind to H3K9me3 and also function as transcriptional co-repressors, such as the tumor 
suppressors Inhibitor of Growth proteins 1 and 2 (ING1/2), that function in 
transcriptional repression and are required for numerous processes related to cell growth 
(Guérillon et al, 2013).  
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Perhaps the most well known group of proteins that bind methylated lysines are 
the zinc-binding PHD containing proteins. While some PHD proteins function as 
transcriptional co-repressors as discussed above, many others function as transcriptional 
co-activators through their popular association with H3K4me3, a well known chromatin 
mark at gene promoters that is associated with active transcription (Santos-Rosa et al, 
2002; Bernstein et al, 2002). PHD-containing proteins that bind to H3K4me3 are often 
associated with acetyltransferases, methyltransferases, as well as transcription factors 
required for transcriptional activation (Musselman & Kutateladze, 2011). Such is the case 
for the PHD containing chromatin effector protein Pygopus, whose hypothesized role is 
to couple active H3K4me3 marks promote further chromatin remodelling events to 
facilitate transcription of genes involved in cell growth and division, as I will discuss in 
subsequent sections. 
 
1.3 The Pygopus family of transcriptional regulators 
The focus of the following sections is on a gene called Pygopus (Pygo) and its 
potential role(s) in cancer. I will describe the initial identification of Pygo and its function 
in the active Wingless/INT1 (Wnt) signalling transcription complex. Finally, I will 
discuss Wnt independent functions of Pygopus and what is known about Pygopus with 
respect to cancer.    
1.3.1 Wnt/-catenin signalling  
 Wnt signalling is a conserved cell signalling pathway that is important to direct 
key aspects of embryonic development and adult stem cell/tissue maintenance. It is 
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involved in both cell proliferation and differentiation, therefore not surprisingly, the 
deregulation and the aberrant activation of Wnt signalling is important in a number of 
human cancers (reviewed in: Clevers and Nusse, 2012). Some of the most well-known 
Wnt target genes are directly involved in promoting cell growth and division, such as 
cyclinD1 (Tetsu & McCormick, 1999; Shtutman et al, 1999) and c-myc (He et al, 1998).  
 In the canonical model, -catenin, the key mediator of Wnt signalling, is normally 
bound to E-cadherin and associated with the cytoskeleton, while unbound -catenin is 
kept at low levels due to a cytoplasmic destruction complex. This complex, which is 
composed of Axin, Adenomatous Polyposis Coli (APC), Casein Kinase 1 (CK1) and 
Glycogen Synthase Kinase 3 (GSK3), is responsible for the binding and 
phosphorylation of -catenin at specific amino (N)-terminal residues, which targets it for 
ubiquitination by -Transducin Repeat Containing Protein (-TrCP) and subsequent 
proteasome mediated degradation (Figure 1.4).  
In the absence of a signal, Wnt target genes in the nucleus are bound by 
complexes of T Cell Factor/Lymphoid Enhancing Factor (TCF/LEF) and 
Groucho/Transducin-like Enhancer (Gro/TLE) family members, which are required to 
recruit HDAC activity to repress the expression Wnt target genes. Wnt signalling is 
initiated by the extracellular binding of a Wnt glycoprotein ligand to the 
Frizzled/Leukemia Related Protein (Fz/LRP) co-receptor. This triggers 
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Figure 1.3. The Wnt signal transduction pathway. For description, see section 1.3.1. 
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the recruitment of Disheveled (Dvl) to the frizzled receptor, which then binds Axin and 
results in the inactivation the -catenin destruction complex. Escaping phosphorylation 
and degradation, -catenin protein accumulates in the cytoplasm and is translocated to 
the nucleus where it displaces Groucho/TLE co-repressor complexes at 
Wnt target genes. -catenin recruits a number of co-activators involved in chromatin 
modification and transcriptional activation, namely Pygopus, which is indirectly bound to 
-catenin though the adaptor protein Legless/B-cell lymphoma 9 (Bcl9) and is required 
for transcriptional activation (reviewed in: Cadigan and Peifer, 2015; Clevers and Nusse, 
2012; Mosimann et al., 2009; Valenta et al., 2012).    
 1.3.2 Pygopus and Wnt signalling 
 Almost two decades ago, a study by Prieve and Waterman (Prieve & Waterman, 
1999) showed that a complex between -catenin and TCF was not sufficient to activate 
Wnt target gene expression and at least one other unknown factor, downstream of -
catenin, was required for Wnt target gene expression. This prompted an investigation by 
at least four groups to identify the unknown factor(s) by performing genetic screens in 
Drosophila to identify factors required for Wingless/Wnt signalling. Early in 2002, there 
were back-to-back publications identifying Pygopus (Thompson et al, 2002; Kramps et 
al, 2002; Belenkaya et al, 2002; Parker et al, 2002) as one of the “unknown factors” 
originally described by Prieve and Waterman. Additionally, in the landmark study by 
Kramps et al. (2002), the authors identified a second protein (legless/Bcl9) was required 
to link Pygopus indirectly to -catenin (Kramps et al, 2002). The mutant phenotypes 
observed in Drosophila lacked legs and antennae and were therefore named legless and 
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Pygopus (the genus of a snake-like legless lizard found in Australia). Concurrently, Lake 
and Kao had isolated a novel cDNA encoding a PHD containing protein from Xenopus 
embryos that was required for embryonic brain development they originally named 
XENA (Xenopus Neural Related), which they later found was the Xenopus homolog of 
Pygopus 2 (Lake & Kao, 2003).  
 The structure of Pygopus proteins is very peculiar, showing little sequence 
similarity to any other proteins, except the carboxy (C)-terminal PHD domain, which is 
common to many proteins that function in H3K4me3 binding and chromatin remodeling, 
as discussed above. At the N-terminus, Pygopus proteins share a conserved region, 
termed the N-terminal homology domain (NHD), which contains a nuclear localization 
sequence (NLS) and a short amino acid sequence (asparagine-proline-phenylalanine; 
NPF) that may be important for the transcriptional activity of Pygopus (Städeli & Basler, 
2005). The PHD and NHD domains of Pygopus are connected by an intervening amino 
acid sequence that is rich in proline and glycine residues (Figure 1.4). 
The function of Pygopus in Wnt signalling depends primarily on its PHD domain, 
which binds directly to legless/Bcl9. Pygopus/BCl9 complexes target -catenin to the 
nucleus required for transcriptional activation of Wnt target genes (Townsley et al, 2004). 
The interface of the PHD domain and Bcl9 binds directly to H3K4me3, which may be 
involved in linking the -catenin complex to active promoters (Fiedler et al, 2008).  
The functional role of the Pygo PHD domain is controversial, since it has been 
shown to be largely dispensable for normal mouse development, except in testes where  
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Figure 1.4. The functional domains of the chromatin effector Pygo2. A cartoon 
illustrating the two functional domains (NHD and PHD) common to Pygo2. Other 
regions of interest include the NLS, required for its nuclear localization and the NPF, 
required at least in part for transcription. Pygo2 interacting proteins are shown in lower 
section. 
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the interaction of Pygo with chromatin depends on its PHD domain (Cantù et al, 2013). 
While the exact role of the NHD in Wnt signalling is not completely understood, several 
studies indicate that it recruits factors that positively affect transcription, including the 
histone acetyltransferases CBP, p300, PCAF and GCN5, histone methyltransferases such 
as the SET domain containing protein Mixed-Lineage Leukemia 2 (MLL2) and factors 
linking it to RNA polymerase II, including the general transcription factor TFIID and the 
mediator complex proteins MED12 and MED13 (Andrews et al, 2009; Chen et al, 2010; 
Carrera et al, 2008; Wright & Tjian, 2009). Many factors that bind the NHD of Pygopus 
also bind directly to -catenin. It therefore has been hypothesized that both -catenin and 
Pygopus may be involved in the cooperative recruitment and binding to factors linking 
the active -catenin transcriptional complex to euchromatin formation and recruitment of 
RNA polymerase (Andrews et al, 2009; Chen et al, 2010).  
Only one Pygopus family member was identified in Drosophila, while in 
mammals, two Pygopus family members (Pygo1 and Pygo2) were identified (Kramps et 
al, 2002). However, of the two family members, Pygo2 appeared to play essential roles in 
development and hence is the more well studied family member. Developmental 
investigations in transgenic mice harboring null alleles for Pygo1 and Pygo2 revealed that 
Pygo1 null mice developed normally with no defects, while Pygo2 null mice die 
neonatally, were smaller in size and displayed defects in lens, kidney, pancreas and hair 
follicle development with occasional exencephaly (Song et al, 2007; Schwab et al, 2007; 
Jonckheere et al, 2008; Li et al, 2007a). Also, Pygo2 was expressed to some degree in all 
adult tissues, whereas the expression of Pygo1 was constrained to heart tissue (Li et al, 
2004).  
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In Drosophila, Pygo was declared to play a dedicated role in Wg signalling 
(Kramps, 2002). Subsequent studies in Pygo2 null mice revealed, however, that while 
some of the observed developmental phenotypes could be attributable to a role for Pygo2 
in Wnt signalling, others could not (Song et al, 2007). These studies, along with several 
others that we will discuss in the following section, revealed that the role of Pygo2 in 
vertebrates can be expanded to include Wnt independent functions.  
1.3.3 Wnt independent functions of Pygo2 
 One could reason that since PHD domains bind to H3K4me3 marks and that all 
active genes display H3K4me3 at their promoters, Pygopus could possibly associate with 
any active gene promoter independently of -catenin and the Wnt signalling complex. 
While this is not likely the case, there is accumulating experimental evidence suggesting 
that Pygo2 also functions outside of the active -catenin transcriptional complex. The 
first experimental evidence suggesting a Wnt independent role for Pygo2 was in Xenopus 
development, where depletion of XPygo2 protein was achieved using morpholinos to 
inhibit translation of XPygo2 mRNA (Lake & Kao, 2003). Pygo2 was required in the 
developing brain for the expression of the well-known Wnt target gene engrailed, but it 
was also required for expression of the non-Wnt target genes Pax6, brain factor 1 and 
retinal homeobox gene 1. This evidence therefore suggested that Pygo2 functions outside 
of the canonical Wnt signalling pathway. Subsequently, several studies have provided 
evidence that Pygo2 also functions outside of Wnt signalling, which I will briefly discuss 
below. 
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 One of the first compelling lines of evidence to suggest a Wnt-independent role 
for Pygo2 was in TOV-21G ovarian cancer cells that do not express -catenin, rendering 
them insensitive to -catenin depletion. In contrast, depletion of Pygo2 had a strong 
growth suppressive phenotype (Popadiuk et al, 2006). Soon after, others reported that in 
the developing mouse lens where Wnt/-catenin signalling is absent, Pygo2 played an 
essential Wnt-independent role in normal development (Song et al, 2007). Furthermore, 
Pygo2 plays a -catenin independent role in the chromatin regulation and transcription of 
both histone genes (Gu et al, 2012) as well as the gene(s) encoding the precursor 
ribosomal RNA (Andrews et al, 2013), as will be discussed in detail in a following 
chapter. Importantly, these results suggested a strong Wnt/-catenin independent 
requirement for Pygo2 in both normal development, as well as in cell growth regulation.  
1.3.2 Pygo2 and cancer 
 The identification of Pygopus and its involvement in Wnt signalling immediately 
associated it a priori with colorectal carcinoma, where -catenin is aberrantly activated 
with high frequency (Kramps et al, 2002; Thompson et al, 2002). However, any direct 
experimental evidence for an involvement of Pygo2 in colorectal cancer was many years 
later (Brembeck et al, 2011), after the expression and requirement of Pygo2 had already 
been established in cancer. We now know that Pygo2 is highly expressed in a number of 
different tumors and cells originating from a variety of tissues compared to their normal 
counterparts. Accordingly, in the following sections, I will review past and present 
literature to summarize what is known about the expression and requirement of Pygo2 in 
cancer. 
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1.3.2.1 Expression of Pygo2 in cancer 
  The first experimental evidence to report the elevated expression of Pygo2 in 
cancer originated from two back-to-back studies in the Kao laboratory. The first study 
was described in epithelial ovarian cancer where Pygo2 mRNA and protein were 
expressed in ovarian cancer cell lines and tumors at levels higher than normal ovarian 
epithelial cells (Popadiuk et al, 2006). The second study showed a similar elevated 
expression of Pygo2 in breast cancer cell lines and tumors (Andrews et al, 2007). Since 
these initial studies, elevated Pygo2 levels were demonstrated in cancers originating from 
the cervix (Tzenov et al, 2013; Andrews et al, 2008), breast (Tzenov et al, 2015), brain 
(Wang et al, 2010; Chen et al, 2011; Wang et al, 2016), intestine (Brembeck et al, 2011), 
lung (Zhou et al, 2014), prostate (Yang et al., 2013; Kao et al., unpublished) and liver 
(Zhang et al, 2015b, 2015a). 
The high level of Pygo2 mRNA in the initial studies in breast and ovarian cancer 
suggested that the expression of Pygo2 was likely upregulated at the transcriptional level. 
Therefore, an investigation of factors that could bind directly to the Pygo2 promoter and 
upregulate its expression in cancer revealed that E-74 like factor 1 (Elf-1) was at least 
one factor that was both required and sufficient to modulate the mRNA expression of 
Pygo2 (Andrews et al, 2008). Significantly, the transcriptional activity of Elf-1 is 
regulated by the tumor suppressor protein Retinoblastoma (Rb) in human T-cells (Wang 
et al, 1993). Furthermore,  Elf-1 mediated expression of Pygo2 appeared to be through an 
Rb-regulated mechanism in an immortalized cervical cell progression model (Tzenov et 
al, 2013). The correlation in expression between Elf-1 and Pygo2 in different cancer 
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types (Andrews et al, 2008) suggested that Pygo2 expression can be regulated by Rb in a 
number of different cancers.  
The link between cell cycle progression and Rb has been well described. For 
example, in quiescent non-dividing cells, Rb exerts its tumor suppressor activity through 
the binding and sequestration of key regulators that drive cell growth and division, such 
as E2F and Elf-1. The function of Rb is inhibited by sequential phosphorylation events 
that eventually lead to the activation of genes that drive cell growth and division 
(reviewed in: Dick and Rubin, 2013; Dyson, 2016). It is not surprising that in a broad 
range of cancers the tumor suppressor activity of Rb is largely compromised through 
mutation and/or its inactivation. These observations suggest that Pygo2 expression may 
be carefully controlled in normal cells and the loss of Rb function in immortal and 
tumorigenic cells results in a consequential upregulation of Pygo2 gene expression. 
1.3.2.2 Requirement of Pygo2 in cell growth 
 Since Pygo2 was highly expressed in cancer cells, the main strategy for 
determining its role and requirement in cancer has been by loss-of-function studies. Here, 
Pygo2 mRNA is reduced or degraded either by RNase H dependent mechanisms using 
antisense oligonucleotides, or by RNA interference (RNAi) dependent mechanisms using 
short interfering (si) or short hairpin (sh) RNAs. Again, the first two studies to show that 
Pygo2 was involved in the malignant growth of cancer cells were published by the Kao 
laboratory (Popadiuk et al, 2006; Andrews et al, 2007). Both studies utilized short 
antisense oligonucleotides that were complementary to the Pygo2 mRNA sequence to 
knock-down expression of the Pygo2 mRNA and hence the protein. Notably, in several 
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ovarian and breast cancer cell lines examined, it was demonstrated that the high 
expression of Pygo2 was required for cell growth.  
Since these initial studies, many examples utilizing RNAi or genetic knock-outs 
demonstrated a role for Pygo2 in cell growth. Intriguingly, Pygo2 has been shown to be 
essential for maintaining the malignant growth characteristics in almost every cancer cell 
type examined. What makes the apparent role of Pygo2 so important for cell growth? To 
answer this question, the literature offers at least two important explanations related to its 
function as a transcriptional regulator.  
Undoubtedly, the first explanation is the imperative role of Pygo2 in Wnt 
signalling, which is important to promote cell growth and division. In normal tissues, 
Wnt signalling is carefully regulated at many levels that occur post-activation and 
function to turn off the pathway. There are many examples of the aberrant activation of 
-catenin in cancer, resulting in the overexpression of proto-oncogenes and proteins that 
drive cell cycle progression, thereby resulting in the activation of a cell growth promoting 
program (reviewed in: Clevers and Nusse, 2012).  
The second explanation comes from the apparent role of Pygo2 as a promiscuous 
chromatin modulator in which it functions aside from its role in the Wnt signalling 
pathway. While the exact mechanism remains elusive, the direct involvement of Pygo2 in 
the chromatin regulation and transcription of histone mRNAs (Gu et al, 2012) and rRNAs 
(Andrews et al, 2013) offers a reasonable explanation for the role of Pygo2 in cell 
growth. Before a cell divides, there is a massive commitment of cellular resources to 
accumulate the adequate biomass required to replicate its DNA and prepare for division. 
Here, biomass accumulation largely depends on the de novo production of DNA and 
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histones, required for chromatin assembly. This process also requires a supplemental 
coordinated increase of ribosome production needed for translation of proteins involved 
in cell growth and division. Therefore, Pygo2 may act as a cell growth effector, required 
to help drive cell cycle progression and cell growth through its involvement in Wnt 
signalling and its concurrent or resultant role in histone and ribosome production.            
1.3.2.3 Pygo2 plays a role in tumor initiation and stem cell expansion. 
 Stem cells possess the quality of self-renewal achieved through both symmetric 
and asymmetric cell division. It is imperative for maintaining a population of the 
founding stem cells, while promoting the clonal expansion of daughter cells. While  
required for normal tissue growth and development, deregulation of stem cell 
proliferation can most certainly result in tumor formation (reviewed in: Kreso and Dick, 
2014). The environment or niche where stem cells reside is vitally important to supply 
the signals necessary to induce stem cell division. For example, Wnt signals that originate 
from the niche cells are important drivers of stem cell division required for adult tissue 
renewal and regeneration (reviewed in: Clevers et al., 2014). Concurrent with these 
functions, there have been several genetic studies in mice implicating a role for Pygo2 in 
stem cell-like expansion, as I will elaborate on below. 
 Pygo2 is expressed in mammary epithelial progenitor cells and while not required 
for their differentiation, it was required for progenitor cell proliferation and expansion 
(Gu et al, 2009). Furthermore, a similar requirement for Pygo2 in the expansion of breast 
cancer stem-like cells was demonstrated (Chen et al, 2010). In both instances, Pygo2 
appeared to play both Wnt and chromatin dependent roles that were required to promote 
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cell proliferation. Importantly, Pygo2 was found to be highly expressed and required for 
tumor initiation and formation in a mouse mammary tumor virus (MMTV)-Wnt1 
transgenic mouse model (Watanabe et al, 2013) as well as for hair follicle progenitor cell 
expansion and skin hyperplasia in a constitutively active -catenin mouse model (Sun et 
al, 2014). Together, these data clearly implicate Pygo2 in stem cell and cancer stem-like 
cell proliferation.   
 
1.4 Thesis rationale and objectives 
 One of the hallmarks of cancer is uncontrolled cell proliferation, encompassing 
both cell growth and cell division. Therefore, targeting cell proliferation mechanisms 
represents a rational avenue for cancer therapy. Cell proliferation is ultimately controlled 
at the transcriptional level, whereby chromatin remodeling and gene expression are 
essential to produce the proteins required to support both cell growth and division. The 
purpose of this thesis is to determine how the Pygo2 chromatin effector affects gene 
expression driving cell proliferation in cancer. To address this question, I examined the 
function of Pygo2 from two different perspectives. The first deals with the chromatin 
remodeling function of Pygo2 within the active Wnt/-catenin signalling complex, while 
the second deals with Pygo2 chromatin remodeling complexes that function outside of 
Wnt signalling. The specific thesis objectives are outlined below.  
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1.4.1 Objective 1: The role of the chromatin effector Pygo2 in Wnt/-catenin 
signalling  
The Wnt signalling pathway supports cell proliferation and expansion during 
normal development and combined with the loss of tumor suppressor function can be 
aberrantly activated to drive cancer growth. Thus, I hypothesized that Pygo2 plays an 
essential role in histone acetylation through the recruitment of HATs, which coordinate 
chromatin remodeling necessary to promote transcriptional activation. In chapter 2, I 
provide evidence that Pygo2 itself is post-translationally modified by acetylation 
specifically by the HAT family members CBP and p300, while in a complex with 
activated -catenin. I therefore hypothesized that acetylation of Pygo2 may regulate its 
chromatin effector function in the active -catenin complex. My results suggest that 
acetylation of Pygo2 likely occurs concurrently with transcriptional activation of the Wnt 
target gene Axin2 and that it may be required subsequently for the transcriptional 
recycling of Pygo2 containing complexes to the cytoplasm. 
1.4.2 Objective 2: Examination of the role of Pygo2 in ribosomal gene expression 
and cell growth 
The hypothesized function of Pygo2 as an integral component of one or more 
chromatin remodelling complexes suggests that its chromatin modulator activity may be 
important for both the Wnt-dependent and Wnt independent expression of genes required 
for cell growth. Previous results in the lab indicated that Pygo2 interacted with Treacle, a 
protein involved in ribosome biogenesis. I therefore hypothesized that the recruitment of 
Pygo2 by Treacle may be necessary for chromatin remodeling and expression of the 
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ribosomal RNA genes. My results suggest that Pygo2 interacts with the transcriptional 
complex within nucleoli and promotes histone H4 acetylation, required for expression of 
the rRNAs.  
 
1.4.3 Objective 3: Analysis of a Pygo2 gene expression program reveals an 
involvement in cell division 
 Continuing forward from objective 2, I found that depletion of Pygo2 triggered 
the nucleolar stress response, which resulted in the activation of the tumor suppressor p53 
and subsequent G1 cell cycle arrest. On the other hand, in tumor cells that do not express 
functional p53, I found that depletion of Pygo2 resulted in reduced rRNA gene 
expression and subsequent G2/M cell cycle arrest.  
Further analysis revealed that Pygo2 depletion resulted in aberrant mitotic spindle 
attachment to kinetochores and a subsequent accumulation of cells in metaphase. Here, I 
hypothesized that Pygo2 may be required for chromatin remodeling and transcription of 
key genes required for cell division. Therefore, to search for direct functional Pygo2 
target genes, I employed a whole genome approach to identify Pygo2 binding sites across 
the genome and coupled this with a whole transcriptome analysis to identify Pygo2 
responsive genes. I found that Pygo2 was required for H3K27 acetylation and the 
expression of a set of genes required to promote cell division.  
Strikingly, some of the key Pygo2 target genes were also targets of the proto-
oncogene c-myc. I therefore hypothesized that Pygo2 may interact with c-myc to promote 
the transcription of genes involved in cell division. I found that Pygo2 interacted with c-
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myc and analysis of Pygo2/c-myc genes revealed that approximately one half of the 
Pygo2 target genes were also co-occupied by c-myc. Furthermore, Pygo2 co-localized 
with c-myc in both nuclei as well as presumptive nucleoli. These results suggest that 
Pygo2 may promote chromatin remodeling of a transcriptional program with c-myc that 
is required for both cell growth and cell division.  
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Chapter 2: Wnt/-catenin dependent acetylation of Pygo2 by CBP/p300 
histone acetyltransferase family members
1
  
                                                 
1
 A version of this Chapter has been published in: Andrews, P.G. and Kao K.R. Wnt/β-
catenin-dependent acetylation of Pygo2 by CBP/p300 histone acetyltransferase family 
members. Biochemical Journal 473(22), pp. 4193-4203, 2016. 
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2.1 Introduction 
The canonical wingless (Wg)/Wnt signal transduction cascade plays important 
roles during normal embryonic and adult tissue development and maintenance. Its 
deregulation at several levels can lead to multiple cancer phenotypes (Clevers & Nusse, 
2012). Wnt target gene transcription relies on the activation of -catenin, which is 
normally associated with the E-cadherin cytoskeleton or kept at low levels in the 
cytoplasm through the action of a destruction complex. Interaction of the Wnt ligand with 
the Frizzled/LRP co-receptor complex inhibits the destruction complex, releasing -
catenin from ubiquitin dependent proteosomal degradation. By an incompletely 
understood mechanism, cytoplasmic -catenin translocates to the nucleus where it 
associates with Wnt target genes via TCF/LEF DNA binding proteins. Its interaction with 
a number of chromatin remodeling factors including Bcl9/Pygopus (Pygo) promote 
enhancer/promoter interactions and euchromatin formation required for transcription, 
reviewed in (Clevers & Nusse, 2012; Mosimann et al, 2009; Valenta et al, 2012; Clevers 
et al, 2014).   
Classically, histone acetytransferases (HATs) promote nucleosomal relaxation 
and the formation of transcriptionally active euchromatin through the catalytic transfer of 
acetyl groups from acetyl-coenzyme A to -amino groups of positively charged lysine 
residues within the N-terminal tails of histones. Conversely, several families of histone 
deacetylases (HDACs) promote transcriptionally silent heterochromatin through the 
removal of the acetyl groups from histones, thereby restoring the positively charged 
lysine residues required for the strong interaction with the negatively charged DNA. 
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Furthermore, lysine residues of non-histone proteins are targets of acetylation resulting in 
consequent positive and negative effects on a plethora of cellular processes (reviewed in: 
(Choudhary et al, 2014; Close et al, 2010; Verdin & Ott, 2014)). 
Nuclear histone acetyltransferases can be divided into CBP/p300, GCN5 related 
N-acetyltransferases (GNATs) and MOZ, Ybf2, Sas3, Sas2, Tip60 (MYST) subfamilies. 
Many transcription factors require the HAT catalytic activity of CBP/p300 to promote an 
open chromatin structure at the vicinity of active target genes, likely by targeting residues 
such as lysine 27 on histone H3 (H3K27), which associate with active gene enhancers 
and prevent polycomb-repressor complex mediated silencing (Tie et al, 2009). GNATs 
also affect histone acetylation on a global scale by targeting the histone residues such as 
H3K9 and H3K14 (Nagy & Tora, 2007). Therefore, it is not surprising that HATs are 
recognized as important targets for the development of anti-cancer therapies (Dawson & 
Kouzarides, 2012). 
It is well established that HATs are integral to Wnt-signalling mediated gene 
expression. For instance, CBP is an essential player in promoting widespread chromatin 
remodeling at the vicinity of Wg target genes (Parker et al, 2008). However, the exact 
role of CBP/p300 in Wnt signalling is complicated and in certain instances, CBP and 
p300 can either activate or repress Wnt target gene transcription (Li et al, 2007b), not 
surprising given their classical roles as tumor suppressors. The context-dependent Wnt 
activation of target genes likely occurs through the usage of CBP or p300 by -catenin, 
which can have distinct phenotypic outputs, such as proliferation versus differentiation 
(Ma et al, 2005). These variable activities may in part result from the direct acetylation of 
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-catenin by different HATs, including CBP and p300. For example, acetylation of -
catenin by CBP inhibits c-myc transcription (Wolf et al, 2002), while acetylation of -
catenin by p300 increases its association with TCF4 and correlates with Wnt target gene 
activation (Lévy et al, 2004). Acetylation and stabilization of -catenin by the p300 CBP 
associated factor (PCAF) is also important for -catenin stabilization and Wnt target gene 
transcription (Ge et al, 2009).    
Pygopus (Pygo) was described  as a dedicated component of the Wnt/-catenin 
transcription complex in Drosophila, tethered to -catenin through Legless/Bcl-9 
(Kramps et al, 2002; Thompson et al, 2002). In vertebrates two Pygo orthologs exist, 
with Pygo2 being the more well characterized protein, having both Wnt-dependent and 
Wnt-independent roles (Song et al, 2007).  Currently, Pygo is postulated to act as a 
chromatin “effector”, in which it binds active H3K4me3 marks through its plant 
homeodomain (PHD; Fiedler et al, 2008), resulting in an induction of open chromatin 
structure by the recruitment of HATs by its N-terminal homology domain (NHD; 
Andrews et al, 2009; Chen et al, 2010).  
The role of Pygo2 in the active TCF/LEF complex may be to recruit HATs, such 
as CBP/p300 and GCN5 and position them so they can co-operatively bind to -catenin, 
required for histone acetylation and Wnt target gene transcription. How Pygo2 is 
prompted to affect the euchromatic conformation is not completely known. I therefore 
examined the interactions of Pygo2 with HATs and found that Pygo2 itself was a 
substrate for CBP/p300-mediated acetylation at specific N-terminal homology domain 
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(NHD) lysine residues when indirectly bound to -catenin, thereby suggesting that Pygo 
acetylation may be important for its role in Wnt target gene activation.    
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2.2 Materials and methods 
2.2.1 Cells and antibodies 
Hela S3 and HEK-293 cells were obtained from the American Type Tissue 
Collection and cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum. Antibodies used included: Pygo2 (Tzenov et al, 2015), Bcl9 
(Kennedy et al, 2010), Pygo2 (Abe109) and H3K4me3 were from Millipore, Myc 
(9E10), p300 (N-15) and CBP (C-20) and were from Santa Cruz Biotechnology, Flag M2 
and -actin were from Sigma Aldrich, acetylated lysine antibodies (9441) were from Cell 
Signalling Technology. 
2.2.2 Plasmids and transfections 
Plasmids used included: pCMV, pCMV-CBP, pCMV-CBP Bro-q and pCS2+--
catenin (Andrews et al, 2009). pcDNA p300 and pcDNA p300-HAT were gifts from 
Warner Greene (Addgene plasmids 23252 and 23254, respectively; Chen et al, 2002), 
pCI flag-PCAF was a gift from Yoshihiro Nakatani (Addgene plasmid 8941; Yang et al, 
1996) and pCMV-flagGCN5 was a gift from Sharon Dent (Addgene plasmid 23098; 
Martínez-Balbás et al, 2000). Full length Myc-tagged Pygo2 and myc-tagged Pygo2 
deletions were PCR amplified from pCS2+-Pygo2 (Popadiuk et al, 2006) and subcloned 
into pCS4+myc. Pygo2 PHD (AA. 1-312) and Pygo2 NHD (AA. 74-406) were PCR 
amplified from pCS2+-Pygo2 using F-5’- GTCCCCCACTCCATGGCCGCCTCG, R-5’- 
TCAGCCAGGGGGTGCCAAGCTGTTG and F-5’- 
GCATCCAACCCTTTTGAAGATGAC, R-5’- TCACCCATCGTTAGCAGCC, 
 44 
 
respectively and inserted into pCS4+myc. All Pygo2 K-R and K-Q mutants were 
constructed using the Quickchange Site Directed Mutagenesis Kit (Stratagene). Bcl9 
HD1 domain was PCR amplified from a human testis cDNA library (Stratagene) and 
inserted into pGEX4T1 using the primer sequences: F-5’- 
CACTCGATGACCCCATCAAATGCTACAGCC and R-5’- 
CCGAAGGGCAGATATCTGTGTGTTCAGAGG. All Plasmids were verified by 
sequencing.  
Plasmids were transfected using Lipofectamine and Plus Reagent (Invitrogen), as 
per the manufacturers’ instructions. TCF-dependent (OT/OF) reporter assays were 
performed exactly as described (Andrews et al, 2009), using pGL3-OT (wild type TCF 
binding sites) and pGL3-OF (mutant TCF binding sites; Shih et al, 2000). Briefly, cells 
were co-transfected with either OT or OF reporters along with equal amounts of pRSV-
gal, pCS2-catenin and pCS2-Pygo2 constructs. Luciferase assays were performed with 
the Luciferase Assay System (Promega) and values were normalized to -galactosidase 
activity and expressed as ratios of OT/OF. All experiments were repeated three times. P-
values were calculated using one-way analysis of variance (ANOVA), using Tukey’s 
multiple comparison test. 
 
2.2.3 RNA extraction and RT-qPCR 
Approximately 2g of RNA was extracted using the RNeasy kit (Qiagen) and was 
used to make cDNA with the Moloney Murine Leukemia Virus (MMLV) Reverse 
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Transcriptase kit (Invitrogen) using random hexamer primers, as per the manufacturers’ 
protocols. For RT-qPCR analysis reactions used RT2 SYBR Green master mix (Qiagen). 
Relative values were calculated using the 2
-ΔΔCt 
method normalized to -actin expression. 
Axin2 (Li & Wang, 2008) primers and -actin (Andrews et al, 2013) primers were 
previously described. P-values were calculated using one-way ANOVA, using Tukey’s 
multiple comparison test. 
 
2.2.4 Immunoprecipitation, GST-pulldown assays and immunoblotting 
Proteins were extracted in radioimmunoprecipitation assay (RIPA) buffer (1.1% 
triton X-100, 0.01% SDS, 1.2mM EDTA, 16.7mM Tris pH8.1 and 167mM NaCl) 
supplemented with 1X protease inhibitors, 1mM phenylmethylsufonyl fluoride and 
10mM sodium butyrate. Immunoprecipitations and immunoblots  were performed exactly 
as described (Andrews et al, 2013). Briefly, immunoprecipitates or approximately 50g 
of protein was denatured in Laemmli sample buffer and separated by sodium dodecyl 
sulfate poly acrylamide gel electrophoresis (SDS-PAGE) and transferred to 
polyvinylidene fluoride membranes. Membranes were then probed with primary and 
secondary antibodies in tris buffered saline with 0.1% tween 20 and 5% skim milk 
powder. Bands were detected by chemilumenescence using Clarity western blot substrate 
(Biorad) and exposed to autoradiography film.  
For immunoprecipitations, protein complexes were captured from approximately 
500g of cell extract and 1-2g of antibody using either protein A or protein G agarose 
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beads. Bound proteins were washed three times with RIPA buffer and two times with 
150mM sodium chloride and eluted using Laemmli sample buffer.  
GST-pulldown assays were performed as described (Andrews et al, 2009).  
Approximately 1g of purified GST proteins grown in Rosetta (Novagen) competent 
cells were purified using glutathione sepharose 4B beads (GE Biosciences). Purified 
proteins were incubated with HEK-293 cell extracts that were transfected with either 
myc-Pygo2 or myc-Pygo2 and CBP, beads were washed three times with RIPA and twice 
with sodium chloride and eluted with Laemmli sample buffer, resolved by SDS-PAGE 
and immunoblots were performed using anti-myc antibodies. After immunoblotting, 
membranes were stained with Ponceau S (Sigma Aldrich). All experiments were repeated 
at least three times. 
2.2.5 Immunofluorescence and quantification of Pygo2 localization 
Immunofluorescence was performed exactly as described (Andrews et al, 2013). 
Briefly, cells were grown on chamber slides and fixed with 4% paraformaldehyde. Fixed 
cells were permeabilized with 0.02% trition X-100 in phosphate buffered saline (PBS). 
Cells were blocked in 10% normal goat and/or donkey serum. Primary and secondary 
(Dylight 488 or Dylight 594 conjugated; Jackson Immunoresearch) antibodies were 
diluted in 1.5% normal serum. Finally, cells were incubated with 4',6-diamidino-2-
phenylindol (DAPI) and mounted in PBS containing 10% glycerol. Images were taken 
using a FluoView FV1000 confocal microscope (Olympus).  
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For quantification of nuclear and nuclear/cytoplasmic Pygo2, HEK-293 cells were 
co-transfected with either CBP or p300 along with empty vector (myc) or myc-tagged 
Pygo2. Cells that were co-stained with myc and CBP or p300 were scored from three 
random fields per experiment with a total number (N) of 573 for EV, 187 for CBP and 
205 for p300. Results shown are means and standard deviations from three separate 
experiments, p-values were calculated using one-way ANOVA, using Tukey’s multiple 
comparison test. 
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2.3 Results 
2.3.1 Pygo2 acetylation is synchronous with -catenin binding and transcriptional 
activation  
Current evidence suggests that Pygo2 functions in the TCF/-catenin 
transcriptional complex to aid in the recruitment of HATs required for target gene 
transcription (Andrews et al, 2009; Chen et al, 2010). In this context, HATs promote 
acetylation of both histone N-terminal tails, as well as other Wnt transcriptional 
components to facilitate transcription. For example, acetylation of -catenin by 
CBP/p300 correlates with an increased affinity for TCF4 and is associated with 
transcriptional activation (Lévy et al, 2004). I therefore hypothesized that Pygo2 may 
also be acetylated when present in a complex with -catenin. HeLa S3 cells were treated 
with LiCl over a time course of six hours to activate TCF/-catenin dependent 
transcription of the Wnt-activated gene Axin2 (Figure 2.1A). Maximum expression of 
Axin2 mRNA in response to LiCl occurred four hours after treatment (p<0.01), 
correlating with an increase in -catenin protein, while Pygo2 and Bcl9 expression 
showed no change in expression (Figure 2.1B; upper panel). Interestingly, there was a 
repression of Axin2 expression at the one hour timepoint. Since Axin2 acts as a feedback 
repressor of activated -catenin (Leung et al, 2002), this may reflect a compensatory 
mechanism to prevent feedback of the pathway at early timepoints following stimulation.   
Endogenous Pygo2 protein was immunoprecipitated at each time point and 
immunoblots were performed to analyze potential Pygo2 acetylation, as well as its  
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Figure 2.1. Pygo2 acetylation correlates with -catenin dependent transcription. (A) 
Temporal analysis of Wnt target gene Axin2 by RT-qPCR in response to 20mM LiCl in 
HeLa S3 cells. Bar graphs indicate means +/- SD. (**p<0.01; B) Pygo2 acetylation 
correlates with its interaction with -catenin. Relative inputs are shown in the upper 
panel. Immunoprecipitation (IP) of endogenous Pygo2 protein from HeLa S3 cells that 
were treated with 20mM LiCl for various timepoints, followed by immunoblotting (IB) 
with antibodies recognizing acetylated Lysine (Ac-K), Bcl9, Pygo2 and -catenin (lower 
panel). -actin was used as a loading control.   
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interactions with Bcl9 and -catenin (Figure 2.1B; lower panel). Pygo2 binding to Bcl9 
did not change significantly in response to LiCl treatment, indicating that their interaction 
is largely independent of active TCF signalling.  Interestingly, Pygo2 was acetylated four 
hours after LiCl treatment, coinciding with its association with -catenin binding and 
Axin2 transcriptional activation. Pygo2 was weakly acetylated at both two and six hours 
after LiCl treatment, straddling its association with -catenin at the 4hr timepoint. These 
observations suggested that temporal acetylation of Pygo was primarily dependent on the 
formation of active TCF/-catenin transcription complexes, however they do not 
preclude the possibility that Pygo2 may be acetylated in the absence of a detectable 
interaction with -catenin. 
2.3.2 Pygo2 is acetylated specifically by CBP/p300 family members 
 The association of Pygo2 acetylation with TCF/-catenin dependent transcription 
prompted a further investigation of the interactions of Pygo2 with HATs such as CBP and 
GCN5. Like that of CBP and GCN5, I found that Pygo2 interacted with both the related 
family members PCAF (GNAT family) and weakly with p300 (CBP/p300 family; Figure 
2.2). The interaction of Pygo2 with the different HAT families raised the possibility that 
Pygo2 is targeted for acetylation by multiple HATs. Myc-Pygo2 was therefore co-
transfected with the HATs: CBP, p300, PCAF and GCN5 (Figure 2.3A). Acetylated 
Pygo2 was detected at the highest level when CBP was co-transfected, but was also 
present when p300 was co-transfected. On the other hand, acetylated Pygo2 was 
undetectable when GCN5 or PCAF was co-transfected, while both GCN5 and PCAF  
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Figure 2.2. Pygo2 interacts with p300 and PCAF. (A) Endogenous Pygo2 was 
immunoprecipitated from HEK-293 cells and the interaction with p300 was detected by 
immunoblotting. (B) HEK-293 cells were co-transfected with myc-Pygo2 and Flag-
PCAF, immunoprecipitations were performed with myc and Flag and show the 
interaction between Pygo2 and the HAT PCAF.  
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Figure 2.3. Pygo2 is acetylated by the CBP/p300 family of HATs. (A) 
Immunoprecipitation of myc-Pygo2 from HEK-293 cells that were co-transfected with 
CBP, p300, PCAF or GCN5, demonstrating that Pygo2 is acetylated by CBP/p300 family 
members (upper panel). Relative inputs are shown in the lower panel. (B) 
Immunoprecipitation of endogenous Pygo2 from HEK-293 cells that were transfected 
with either pCMV or pCMV-CBP, showing the acetylation of endogenous Pygo2 by 
CBP. (C) HEK-293 cells were co-transfected with myc-Pygo2 and a catalytic fragment of 
CBP (Flag-Bro-Q), immunoprecipitations were performed with anti-myc or anti-GST as 
a negative control and probed with an anti-acetyl lysine antibody. (D) 
Immunoprecipitation of myc-Pygo2 from HEK-293 cells that were co-transfected with 
either wild-type CBP and p300 or HAT mutated (-HAT) CBP and p300, followed by 
immunoblotting for Ac-K and myc. IgG denotes the relative position of the IgG heavy 
chain.  
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acetylated c-myc (Figure 2.4) as a positive control (Patel et al, 2004). Therefore, these 
results indicated that Pygo2 was specifically acetylated by CBP/p300 family members. 
Endogenous Pygo2 protein was strongly acetylated when we introduced CBP into 
HEK293 cells confirming in vivo, the foregoing observations (Figure 2.3B). Moreover, 
when exogenous myc-Pygo2 was introduced along with the catalytic HAT domain-
containing fragment of CBP (Bro-Q) in HEK293 cells, acetylated myc-Pygo2 was readily 
detectable by immunoprecipitation with anti-myc, but not anti-GST as a negative control 
(Figure 2.3C).  
Finally, to show that acetylation of Pygo2 was specific to CBP and p300 family 
members, catalytic HAT domain mutants of CBP and p300 were co-transfected with 
myc-Pygo2, resulting in a significant decrease in the amount of detectable Pygo2 
acetylation (Figure 2.3D). These results indicated that while it is possible for Pygo2 to 
bind to multiple HATs, it was acetylated specifically by CBP and p300. 
2.3.3 NHD lysine residues of Pygo2 are targeted for CBP and p300 dependent 
acetylation 
 To determine the regions of Pygo2 that were acetylated by CBP/p300, two Pygo2 
mutants were used in which either the NHD or PHD domain was deleted (Figure 2.5A). 
The PHD-deleted mutant (PHD) was detectably acetylated, indicating that CBP could 
acetylate Pygo2 directly, independent of its interaction with Bcl9/-catenin. Consistent 
with this observation, acetylation of a Bcl9 binding mutant of Pygo2 was not significantly 
different compared to wild-type Pygo2 (Figure 2.6A). However, acetylation of PHD  
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Figure 2.4. PCAF and GCN5 acetylate myc. To demonstrate that overexpressed PCAF 
and GCN5 constructs are catalytically functional, HEK-293 cells were co-transfected 
with the bonafide PCAF/GCN5 substrate c-myc. Myc-tagged c-myc (MT-myc) was 
immunoprecipitated with anti-myc antibodies and immunoblots were performed with 
anti-acetylated Lysine antibodies to demonstrate acetylation of c-myc by PCAF/GCN5.  
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Figure 2.5. Pygo2 acetylation requires the NHD and is acetylated at specific NHD 
lysine residues. (A) The Bro-Q domain of CBP (Flag tagged) was co-transfected with 
myc-tagged wild-type Pygo2, Pygo2 lacking the NHD (NHD), or Pygo2 lacking the 
PHD (PHD), immunoprecipitations were performed with anti-myc and immunoblots 
were performed with Ac-K and myc. (B) Immunoprecipitation of myc-Pygo2 lysine-
Arginine (K-R) point mutants from HEK-293 cells that were co-transfected with CBP, 
followed by immunoblotting for Ac-K.  
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Figure 2.6. Acetylation of Pygo2 does not affect Bcl9 binding. (A) Myc-Pygo2 and a 
Bcl-9 binding mutant of Pygo2 (PHD mut; T363A, A366V) were immunoprecipitated 
from HEK-293 cells that were co-transfected with CBP Bro-Q, relative Pygo2 acetylation 
was assessed by immunoblotting. (B) GST-pulldown analysis of Pygo2 (with and without 
CBP) and GST-HD1 of Bcl9, showing no differences in the ability of Pygo2 to bind to 
the HD1 region of Bcl9 (C) Myc or myc-Pygo2 was immunoprecipitated from HEK-293 
cell extracts that were co-transfected with either empty vector or CBP Bro-Q and the 
relative binding of endogenous Bcl9 to Pygo2 or acetylated Pygo was assessed by 
immunoblot.   
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was lower compared to its wild-type counterpart, indicating that its interaction with 
H3K4me2/3 may be important for complete Pygo2 acetylation by CBP. In contrast, the 
NHD region was essential for direct Pygo2 acetylation by the catalytic fragment of CBP, 
consistent with the observation that Pygo2 interacts with CBP through its NHD.  
To identify the acetylation sites, single point mutants of Pygo2 were constructed 
substituting Lysine residues with Arginine, which cannot be acetylated, while 
maintaining the positive charge. When the Pygo2 K-R mutants were co-transfected with 
full length CBP, acetylation was qualitatively reduced in two Pygo2 constructs. One 
construct contained a single Arginine substitution at Lysine 11 (K11R), consistent with 
the findings of a study that identified more than 8100 acetylation sites in HeLa cells 
(Scholz et al, 2015), while the other construct contained three Arginine substitutions at 
Lysines 43, 44 and 47 (K43, 44, 47R; Figure 2.5B). Together, these results indicated that 
Pygo2 was highly acetylated at specific residues of its NHD, where it interacts with CBP.  
2.3.4 Pygo2 complex formation with Bcl9/-catenin and HATs occurs independently 
of Pygo2 acetylation 
Since Pygo2 acetylation correlated with binding to -catenin and transcriptional 
activation of Axin2 (Figure 2.1), I hypothesized that Pygo2 acetylation may be a 
requirement for its association with other components in the active Wnt transcription 
complex. First the interaction of Pygo2 with Bcl9 was examined, since it is the primary 
link between Pygo and -catenin (Kramps et al, 2002). LiCl treatment did not result in 
any change in the ability for Pygo2 to bind Bcl9 (Figure 2.1). To confirm that this 
interaction was independent of acetylation both in vitro GST-pulldowns were performed 
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using the Pygo binding HD1 domain, as well as immunoprecipitations from cells and I 
found no difference in the ability of acetylated Pygo2 to bind to Bcl9 (Figure 2.6B and 
C). This result suggested that Pygo2 acetylation does not affect its interaction with Bcl9 
and hence its interaction with -catenin.  
For Wnt-mediated transcriptional activation Pygo2 binds HAT complexes in 
conjunction with -catenin to promote chromatin remodeling. Indeed, overexpression of 
CBP (Figure 2.7A) and p300 (Figure 2.7B) correlated with both Pygo2 acetylation and 
increased GCN5 binding. Acetylation of Pygo2 and its association with GCN5 were 
significantly decreased in the presence of both CBP and p300 HAT mutants relative to 
wild type CBP and p300 (Figure 4.7A and Figure 4.7B). Thus, the interaction between 
Pygo2 and GCN5 correlated with CBP/p300-dependent HAT acetylation of Pygo2. 
Paradoxically, while Pygo2 was acetylated in the presence of only the Bro-Q catalytic 
fragment of CBP, the Pygo2-GCN5 interaction was, on the other hand, inhibited (Figure 
2.7C). This suggests the increased interaction of Pygo2 with GCN5 was dependent on its 
association with full length CBP, rather than indiscriminate Pygo2 acetylation.  
To further investigate the nature of its interaction with GCN5, Pygo2 was mutated 
with three Lysine substitutions (K11R, K43R, K44R; 3K-R) and tested for its ability to 
be acetylated by CBP and to interact with GCN5. While Pygo2 3K-R showed a 
significant reduction in CBP-mediated acetylation, the interaction of Pygo2 with GCN5 
remained unaffected when immunoprecipitation assays were performed for both Pygo2 
(myc) and GCN5 (Flag; Figure 2.8A). Consistently, an acetylation mimic of the same  
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Figure 2.7. CBP and p300 correlate with an increased binding of Pygo2 to GCN5. 
(A) Immunoprecipitation of myc-Pygo2 from HEK-293 cells that were co-transfected 
with CBP or CBP HAT mutant (HAT mut), showing increased binding Pygo2 to GCN5, 
that requires catalytically active CBP, but is independent of Pygo2 acetylation. (B) 
Immunoprecipitation of myc-Pygo2 from HEK-293 cells that were co-transfected with 
p300 or p300 HAT mutant (HAT), showing increased binding Pygo2 to GCN5, that 
requires catalytically active p300, but is independent of Pygo2 acetylation. (C) 
Immunoprecipitation of myc-Pygo2 from HEK-293 cells that were co-transfected with 
the catalytic C-terminal half of CBP (Flag-Bro-Q), showing the interaction between 
Pygo2 and GCN5 is inhibited.  
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Figure 2.8. GCN5 binds to Pygo2 independent of Pygo2 acetylation. (A) Forward and 
reverse immunoprecipitations of myc-Pygo2 and a Pygo2 acetylation deficient mutant 
(3K-R) from HEK-293 cells that were co-transfected with Flag-GCN5 and CBP, showing 
acetylation of Pygo2 has little effect on its ability to bind GCN5. (B) 
Immunoprecipitation of myc-Pygo2, a Pygo2 acetylation deficient mutant (3K-R) and a 
Pygo2 acetylation mimic mutant (3K-Q) from HEK-293 cells that were co-transfected 
with Flag-GCN5, showing little effect on the ability of Pygo2 to bind GCN5. (C) 
Luciferase assay measuring TCF/-catenin dependent transcription (OT/OF) in HEK293 
cells co-transfected with wild-type (WT) and mutant Pygo2 constructs along with -
catenin (Top panel) and a representative immunoblot confirming the overexpression of 
Pygo2 and -catenin (Bottom panel; **p<0.01, NS; not significant).  
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residues of Pygo2 (3K-Q) showed little difference in the ability of Pygo2 to bind to 
GCN5 (Figure 2.8B).  
While acetylation was not required for GCN5 binding, to confirm its functional 
importance in complex formation, the ability for mutant Pygo2 to activate TCF-
dependent transcription was tested in the presence of -catenin in HEK293 cells. As 
expected, the acetylation mimic Pygo2 mutant (3K-Q) activated TCF dependent 
transcription to similar levels as wild-type (p<0.01), while acetylation defective Pygo2 
(3K-R) showed little activation of TCF dependent transcription, compared to the control 
(p=NS; Figure 2.8C).  
These observations confirmed that GCN5 interacts with Pygo2 independently of 
its acetylation status, and suggest that while CBP/p300–dependent acetylation of Pygo2 is 
associated with active Wnt complex formation, it is not specifically required for 
interaction with individual components of the complex. 
2.3.5 Regulation of Pygo2 subcellular localization by p300 mediated acetylation 
Mutation analyses revealed that Pygo2 was acetylated by CBP at residues K43, 44 
and 47, encompassing the putative Pygo2 nuclear localization sequence (NLS; Figure 
2.5). Furthermore, we determined that Lysine 44 was important for Pygo2 nuclear 
localization, when substituted with Arginine (Figure 2.9). To test whether sub-cellular 
localization affected Pygo2 acetylation, an unrelated Pygo2 NLS mutant (RRK-AAA) 
was transfected, which is retained in the cytoplasm (Figure 2.10A), and showed no 
differences in acetylation compared to wild type Pygo2 (Figure 2.10B). While these  
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Figure 2.9. Subcellular localization of myc-Pygo2 K->R mutants in HEK-293 cells. 
293 cells were transiently transfected with myc-Pygo2 K-R mutants and were visualized 
by immunofluorescence, revealing that lysine 44 is important for Pygo2 nuclear 
localization. DAPI was used to stain and visualize the nuclei. Scale bar = 50m.   
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Figure 2.10. Cytoplasmic Pygo2 can be acetylated by CBP. (A) HEK-293 cells were 
transfected with myc-Pygo2 and myc-Pygo2 with an NLS mutation (RRK-AAA), 
confocal images show cytoplasmic localization of myc-Pygo2 (RRK-AAA), scale bar = 
20m. (B) Cytoplasmic Pygo2 is acetylated by CBP. HEK-293 cells were co-transfected 
with wild type myc-Pygo2 or NLS mutant myc-Pygo2 (RRK-AAA) along with the 
catalytic region of CBP (Flag- Bro-Q), myc-Pygo2 were immunoprecipitated and 
immunoblotted using anti-acetyl lysine, showing little difference in acetylation of nuclear 
or cytoplasmic Pygo2.   
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results do not indicate in which subcellular compartment Pygo2 is acetylated, they 
suggest that subcellular localization of Pygo2 may not important for direct CBP mediated 
acetylation.  
On the other hand, I investigated whether acetylation of Pygo2 affected 
subcellular localization. Initially, I determined whether CBP or p300 could alter the 
subcellular localization of Pygo2. When wild type myc-Pygo2 was co-transfected with 
empty vector or CBP, approximately 80% of the cells displayed nuclear retention of myc-
Pygo2 protein with the remaining 20% showing distribution to both cytoplasm and 
nucleus (p<0.001; Figure 2.11; lower panel). However, co-transfection of Pygo2 with 
p300, resulted in a marked increase in the proportion of cells with cytoplasmic Pygo2 
(p<0.001), suggesting that acetylation of Pygo2 by p300 may promote cytoplasmic Pygo2 
subcellular shuttling.  
I next tested whether preventing CBP/p300 mediated acetylation of NLS residues 
could affect Pygo2 subcellular localization. Construction of additional single K-R point 
mutants revealed that mutation of Lysines 43 and 44 resulted in a reduced acetylation of 
Pygo2 (Figure 2.12A). Consistent with a potential role in subcellular localization, all 
three acetylation mimic mutants of the two NLS Lysines (K43Q, K44Q and K43, 44Q) 
rendered Pygo2 cytoplasmic (Figure 2.12B), thereby suggesting that acetylation of any 
one of these residues by p300 promotes cytoplasmic localization of Pygo2.  
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Figure 2.11. p300 targets a fraction of Pygo2 to the cytoplasm. HEK-293 cells were 
co-transfected with myc-Pygo2 along with empty vector, CBP or p300 and myc cells 
were scored based on the nuclear or nuclear + cytoplasmic staining, results represent 
means +/- standard deviation (bottom panel). Representative confocal images showing 
staining of myc-Pygo2 with CBP or p300 are in the top panel. Scale bar = 5m 
(***p<0.001).  
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Figure 2.12. Acetylation of Pygo2 NLS lysines. (A) Immunoprecipitation of myc-Pygo2 
NLS point mutants from HEK-293 cells that were co-transfected with CBP, immunoblots 
were performed with anti-Ac-K antibodies. (B) Sub-cellular localization of myc-Pygo2 
acetylation mimic mutants, showing that K43 or K44 targeted acetylation alone or in 
combination results in cytoplasmic localization. DAPI was used to stain and visualize the 
nuclei. Scale bar = 20m.   
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2.4 Discussion 
Our group previously demonstrated that CBP was associated with Pygo2 
dependent transcriptional activation (Andrews et al, 2009). In concordance with this 
finding, I demonstrated that Pygo2 is functionally regulated by CBP/p300 mediated 
acetylation and is associated with Wnt-dependent Axin2 gene activation. It is likely that 
recruitment of CBP/p300 by the -catenin-Bcl9-Pygo complex is required to promote an 
amenable conformation necessary to accommodate Pygo2 acetylation. While coupled to 
active -catenin, I propose that upon recruitment of CBP/p300, Pygo2 acetylation occurs 
concurrent with histone acetylation, consistent with widespread histone acetylation 
associated with CBP observed at Wg target genes (Parker et al, 2008). These 
observations suggest that the association of Pygo2 with CBP/p300 may be required to 
initiate active -catenin complex assembly. While Pygo2 acetylation does not appear to 
be required for complex assembly, it may occur as a result of active complex formation 
which is likely coupled to histone acetylation (Figure 2.13, panel i) and may play a role in 
subsequent dissociation and shuttling of Pygo2-associated complexes from Wnt target 
genes following transcriptional initiation (Figure 2.13, panel ii). 
 Non-redundant usage of CBP and p300 by -catenin can result in different and 
distinct outcomes (Ma et al, 2005; Teo & Kahn, 2010); interestingly, the utilization of 
CBP by -catenin can result in cell proliferation, but with p300, in differentiation. 
Similarly, the alternate acetylation of Pygo2 by CBP and p300 might also be related to 
different cellular outcomes. For example, Pygo2 acetylation by p300 promoted a fraction  
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Figure 2.13. Proposed model of Pygo2 acetylation. (i) HAT complex recruitment by 
Pygo2 results in transcriptional initiation/activation, as well as associated Pygo2 and 
histone acetylation. (ii) Acetylated Pygo2 complex dissociates from chromatin 
immediately following initiation of transcription.   
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of Pygo2 to localize to the cytoplasm (Figure 2.11), perhaps relating to a differentiation-
like phenotype. On the other hand, Pygo2 acetylation by CBP resulted in the nuclear 
retention of Pygo2 (Figure 2.11), suggesting that nuclear Pygo2 is related to a 
proliferative phenotype, consistent with a role for Pygo2 in the proliferation of cancer 
cells where it is localized to nuclei (Andrews et al, 2013; Tzenov et al, 2015; Andrews et 
al, 2007, 2008; Popadiuk et al, 2006; Liu et al, 2013; Watanabe et al, 2013). 
My results support the hypothesis that Pygo2 binds to multiple HATs in the -
catenin transcriptional complex, which is thought to be imperative for promoting histone 
acetylation and transcriptional activation (Andrews et al, 2009; Chen et al, 2010). 
Interestingly, both CBP and p300 promoted an increased association of GCN5 that was 
dependent on a functional catalytic domain, but not directly on Pygo2 acetylation (Figure 
2.7 and 2.8), suggesting the catalytic domain of CBP/p300 is important for the binding of 
GCN5 to Pygo2. Since -catenin has been shown to bind to the N-terminal CH1 domain 
of CBP (Sun et al, 2000) and Pygo2 was shown to bind to the C-terminal CH3 domain of 
CBP (Andrews et al, 2009), I propose that the interaction of Pygo with CBP/p300 likely 
acts in concert with -catenin to recruit HAT activity required for gene activation. The 
involvement of a multiprotein complex consisting of many HATs, including CBP/p300 
and GCN5 family members, is consistent with findings demonstrating that GCN5/PCAF 
can directly associate with CBP/p300 (Yang et al, 1996; Roth & Iol, 1998). Interestingly, 
the interaction of Pygo2 with GCN5 required full length CBP, since expression of the C-
terminal half (Bro-Q) of CBP resulted in a competition for GCN5 binding, further 
highlighting the importance of Pygo2 in HAT complex formation.  
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Acetylation of Pygo2 did not appear to affect Bcl9 binding (Figure 2.1 and 2.6), 
suggesting that Pygo2 and Bcl9 constitute a functional complex that is independent of, 
but required for Wnt target gene transcription as was demonstrated previously (Kennedy 
et al, 2010). The correlation of Pygo2 acetylation with transcriptional activation and -
catenin binding suggests a scenario in which Pygo2 is modified only when it is present in 
a complex with active -catenin and is quickly de-acetylated upon release from the 
complex (Figure 2.1). This model is consistent with observations in which the 
adenomatous polyposis coli (APC) protein was shown to cycle on and off of the c-myc 
enhancer in response to Wnt activation (Sierra et al, 2006), demonstrating the temporal 
binding of Pygo to chromatin was strongly associated with -catenin, Bcl9 and p300 and 
inversely correlated with histone deacetylase binding to the c-myc enhancer.  
My results extend previous findings and suggest that Pygo2 acetylation may be 
important during or after active -catenin complex assembly. It may play a role in post-
transcriptional recycling of the TCF/-catenin transcription complex via its subsequent 
displacement to the cytoplasm once transcription initiation has occurred. Most 
significantly, my results indicate that the association of Pygo2 with HATs and acetylation 
of Pygo2 by CBP/p300 is important in the regulation of TCF/LEF target gene 
transcription, further underscoring the importance of the chromatin effector function of 
Pygo2 in Wnt signalling.  
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Chapter 3: Evidence of a novel role for Pygopus in ribosomal RNA 
transcription
2
  
                                                 
2
 A version of this Chapter has been published in: Evidence of a novel role for Pygopus 
in rRNA transcription. Biochemical Journal 453(1), pp. 61-70, 2013. 
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3.1 Introduction 
 Several ribosomes are required for each messenger RNA translated by a 
eukaryotic cell. Therefore, a significant proportion of cellular resources are devoted to the 
production of ribosomes, especially during cell growth and division. An important, initial 
step in ribosome biogenesis is the transcription of the 47S pre-ribosomal (r) RNA by 
RNA polymerase I (Pol I), a process finely tuned to respond to environmental cues, such 
as nutrient availability and growth factors (Moss, 2004; Moss et al, 2007; Russell & 
Zomerdijk, 2005). The recruitment of Pol I to sites of rRNA transcription is facilitated by 
structural and regulatory proteins such as: upstream binding factor (UBF), selectivity 
factor 1 (SL-1) and Treacle (Prieto & McStay, 2007). Once transcribed, the pre-rRNA 
undergoes a variety of post-transcriptional (maturation) modifications, before being 
cleaved into smaller subunits. The cleaved rRNAs are assembled with a number of 
ribosomal proteins (RPs) into mature ribosomal subunits and exported from the nucleolus 
to the cytoplasm.  
 While there are hundreds of tandemly arrayed rDNA gene repeats, about half are 
normally transcriptionally silent (McStay & Grummt, 2008). Ribosome requirements are 
met either by adjusting the rate of transcription from active rDNA genes, and/or by 
increasing the number of active repeats through epigenetic modulation. The mechanisms 
that form silent, heterochromatic rDNA are well-established, but much less is known 
about factors such as histone modification, that initiate or maintain actively transcribing 
euchromatic rDNA (McStay & Grummt, 2008). For instance, how do cells actively 
engaged in proliferation, such as required for development or malignant growth, 
epigenetically raise rRNA transcript production? 
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Pygopus (Pygo) proteins (Kramps et al, 2002; Thompson et al, 2002) function in 
chromatin remodeling for transcription at active Wnt target genes via interpretation of the 
histone code. Pygo binds to histone H3 trimethylated at Lysine 4 (H3K4me3) through its 
C-terminal plant homeodomain (Fiedler et al, 2008; Gu et al, 2009), while its N-terminal 
homology domain (NHD) can recruit histone acetyltransferase (HAT) activity, which can 
augment target gene activation (Andrews et al, 2009; Chen et al, 2010). These 
observations uniquely place Pygo in a position whereby it can read histone marks 
(H3K4me3) and promote further histone modification such as acetylation, associated 
with gene activation.  
The chromatin remodeling function of Pygo may not be entirely restricted to Wnt 
signalling, as Pygo proteins have additional uncharacterized Wnt-independent roles in 
lens development (Song et al, 2007) and malignant growth (Popadiuk et al, 2006). To 
elucidate Wnt-independent roles of Pygo2, potential interactions were investigated with 
cellular proteins using well-established human cancer cell lines. The results presented 
here suggested a novel requirement for Pygo2 that would address how these proliferating 
cells adapt to their increased demand for ribosomes. In both in vivo and in vitro analyses, 
Pygo2 interacted with Treacle, a nucleolar phosphoprotein required for ribosome 
biogenesis in neural crest derived craniofacial structures (Sakai & Trainor, 2009). 
Additionally, Pygo2 was detected interacting with UBF-1, a protein required for rDNA 
promoter architecture and rRNA transcription (Sanij & Hannan, 2009), in the nucleoli of 
cancer cells and was associated with Pol I-associated transcription complexes at the 
rDNA promoters. Using RNA interference, depletion of Pygo2 resulted in a reduction of 
histone H4 acetylation at rDNA promoters and reduced transcription of the pre-rRNA 
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transcript in both p53 positive and negative cells. In p53 positive cells, reduction of Pygo 
triggered the nucleolar stress response, resulting in activation of the ribosomal protein 
(RP)-mdm2-p53 pathway and subsequent cell cycle arrest. These findings suggest a novel 
role for Pygopus in ribosome biogenesis, and that Pygopus promotes euchromatin 
formation at the vicinity of active rDNA genes, a requirement for proliferative growth.  
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3.2 Materials and methods 
3.2.1 Cell lines, plasmids and Antibodies 
 Cell lines were obtained from the American Type Culture Collection, maintained 
in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS (Invitrogen) and 
cultured at 37°C with 5% CO2. All GST-Pygo2 constructs have been previously reported 
(Andrews et al, 2009). All constructs were verified by sequencing.  
Antisera raised against Pygo2 have been described elsewhere (Popadiuk et al, 
2006). Treacle (H-90), UBF-1 (F-9), p53 (DO-1), p21 (C-19) and RPA194 (H-300) 
antibodies were purchased from Santa Cruz; Phospho-cdc2 (Tyr 15), Cyclin A (BF683), 
p21 (12D1) and Cyclin B1 antibodies from Cell Signalling; Pygo2, H3K4me3, Ac-H3 
and Ac-H4 antibodies from Millipore; Treacle, -Actin and BrdU antibodies from Sigma, 
and Fibrillarin and RPL11 antibodies from Abcam. Other antibodies used include: -
tubulin (Pharmingen), B23 (Zymed) and Nop56 (Abnova). 
3.2.2 GST-pulldowns, immunoprecipitation and proteomics 
 GST-pulldown and immunoprecipitation analyses were performed using reagents 
and buffer conditions essentially as described (Andrews et al, 2009). Briefly, 
approximately one mg of purified GST-Pygo2 fusion protein, grown in Rosetta 
(Novagen) cells, was incubated with 35S-radiolabelled Treacle, washed extensively, 
separated by SDS-PAGE, stained with Coomassie blue R-250 (Biorad) and exposed to 
autoradiography film. 
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3.2.3 Immunofluorescence 
 Cells were processed and stained for immunofluorescence as previously described 
(Andrews et al, 2009). Detection of Pygo2 was performed using anti-Pygo2 (Millipore; 
ABE109). For actinomycin D experiments, HeLa cells were treated with 50ng/ml 
actinomycin D (Sigma) or ethanol carrier for 2 hours at 37°C, 5% CO2 and immediately 
fixed in 4% paraformaldehyde and processed.  
The bromouridine (BrUTP; Sigma) incorporation assay was performed exactly as 
described (Sweet et al, 2008). Cells were subsequently incubated with BrdU and Pygo2 
antibodies (1:100 in PBS with 0.05 units/ml of RNase inhibitor) overnight at 4°C, stained 
with a mixture of Cy5-conjugated anti-mouse IgG and FITC-conjugated anti-rabbit IgG 
(Jackson Immunoresearch) and imaged on an Olympus FluoView FV1000 confocal 
microscope. 
3.3.3 Nucleolar fractionation 
 Nuclei and nucleoli were isolated by sucrose density centrifugation as exactly as 
described (Andersen et al, 2002), imaged using phase-contrast microscopy and 
immunoblotted for detection of cytoplasmic, nuclear and nucleolar markers. Extracts of 
whole cells, nuclei and nucleoli were prepared in Laemmli sample buffer. 
3.3.4 Chromatin Immunoprecipitation 
 ChIP assays were performed as previously described (Andrews et al, 2008). 
Briefly, sonication was performed on formaldehyde cross-linked cells to produce 
genomic DNA fragments approximately 500bp in size. 400 g of precleared chromatin 
was subject to immunoprecipitation with 2 mg of antibodies against RPA194, UBF-1, 
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Treacle, Pygo2, H3K4me3, Ac-H3 and Ac-H4. Normal rabbit and normal mouse IgGs 
were used as negative immunoprecipitation controls. After washing, formaldehyde 
crosslinks were reversed at 65°C. Samples were subsequently treated with RNase A and 
proteinase K. DNA was then purified using the Qiaquick PCR purification kit (Qiagen, 
Ontario, Canada). For re-ChIP experiments, complexes were first eluted with 10mM 
dithiothreitol (DTT) for 30 minutes at 37°C, diluted 20X with RIPA buffer supplemented 
with protease inhibitors and then subjected to a second round of immunoprecipitation. 
Primer sequences given in Table 3.1 or primers recognizing the rDNA core promoter 
(Ghoshal et al, 2004) and the ITS-1 regions (Gorski et al, 2007). 
3.3.5 Quantitative (q) PCR 
 RT-qPCR was performed as described [39], using RT2 SYBR green master mix 
(SA Biosciences, Mississauga, Canada). Oligonucleotide primers targeting Pygo2 
(Andrews et al, 2008) and 47S (Table 3.1) were used and results were normalized to 
levels of -actin mRNA. For ChIP-qPCR analysis, rDNA promoter occupancy was 
calculated relative to that of the input chromatin. P-values were calculated using one-way 
ANOVA, using Tukey’s multiple comparison test. 
3.3.6 RNAi 
 Cells were grown to approximately 25% confluency and all siRNAs were 
transfected to a final concentration of 5nM using Lipofectamine RNAiMax (Invitrogen), 
according to the manufacturers’ protocol. The two Pygo2-specific and NTC (a 5 base 
mismatch control of hpy2-Z, mismatches are underlined in sequence) siRNAs were  
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Table 3.1 - Primer sequences 
Amplicon 5’ primer 3’ primer Reference 
rDNA promoter 5’-GGTATATCTTT-
CGCTCCGAG 
5’-GACGACAGGTC-
GCCAGAGGA 
(O’Sullivan et 
al, 2002) 
ITS-1 5’-CGTTCGTTCGC- 
TCGCTCGTTC 
5’-CAAGGGGTCTTT-
AAACCTCCGC 
(Andrews et 
al, 2013) 
Axin2 5’- CTGGCTTTGGT- 
GAACTGTTG 
5’- AGTTGCTCAC- 
AGCCAAGACA 
(Li & Wang, 
2008) 
Pygo2 5’-GTCCCCCACTCCA-
TGGCCGCCTCG 
5’-TCGCTTCTTTT-
CTGGACTCTTC 
(Andrews et 
al, 2008) 
p21 5’-GATGTCCGTCA-
GAACCCATGC 
5’-CAAAGTCGAAGT-
TCCATCGCTC 
(Andrews et 
al, 2013) 
47S 5’-CGTGCGTGTCA-
GGCGTTCTC 
5’-CCGCAAGTCGA-
CAACCACTGG 
(Andrews et 
al, 2013) 
Actin 5’-
ATCTGGCACCACACC-
TTCTACAATGAGCTGCG 
5’-ATGGCTGGGGT-
GTTGAAGGTCTC 
(Andrews et 
al, 2008) 
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designed using the siDESIGN Center (dharmacon.com) and purchased from Dharmacon 
(The sense strand sequences are: GGAGACAGCUUUAGGGAAUUU (hpy2-X), 
GGAGUGAGGUGAACGAUGAUU (hpy2-Z) and GGACUGUGGUCAACCAUGUUU 
(NTC). The Pygo2 siRNAs were analyzed using the Basic Local Alignment Search Tool 
(BLAST; NCBI) to confirm target specificity. The p53 siRNA was purchased as the 
TP53 siGENOME SMARTpool (Dharmacon).  
3.3.7 Metabolic labeling 
 HeLa cells were transfected with siRNAs 48 hours prior to metabolic labeling 
using a modified protocol (Pestov et al, 2008). Briefly, cells were washed with 1X PBS 
and the media was replaced with DMEM containing 5 Ci/ml of 3H Uridine and 
incubated for 30 minutes at 37°C. The labeling medium was then chased with DMEM 
containing 1 mg/ml unlabeled Uridine. RNA was extracted 120 minutes later using Tri-
Reagent (Ambion). Approximately 10 g of RNA was separated on MOPS-formaldehyde 
gels, transferred to nylon membranes, cross-linked, dried and sprayed with En3Hance 
(Perkin Elmer) and exposed to autoradiography film. 
 
3.3.8 Fluorescence activated cell sorting (FACS) 
Initially, HeLa cells were treated with siRNAs for 48 hours. Cells were collected 
and fixed with 2% formaldehyde for 10 minutes at 37°C and then incubated in 90% 
methanol/PBS for 30 minutes at 4°C. Cells were then resuspended in 1XPBS treated with 
20 g/ml RNase A for 20 minutes at 37°C, stained with 1mg/ml propidium iodide and 
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counted in a BD FACS Calibur flow cytometer. P-values were calculated using one-way 
ANOVA, using Tukey’s multiple comparison test.   
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3.3 Results 
3.3.1 Pygo2 interacts with Treacle and UBF-1 and is detected in nucleoli of cancer 
cells 
 Previous studies in the lab using tandem mass spectrometry to investigate novel 
functions of Pygo2 were performed to identify interacting proteins with the NHD of 
Pygo2 from MCF-7 breast cancer cells. One band in particular at about 205kD matched 
identically to the primary sequence of Treacle, a protein required for the increase in 
rRNA production that supports proliferation of anterior neural crest cells (Valdez et al, 
2004; Jones et al, 2008). Therefore, it was hypothesized that previously reported growth 
requirements for Pygo2 in cancer cells may be related to a potential role in rRNA 
production. 
To confirm the interaction between Pygo2 and Treacle, endogenous Pygo2 was 
immunoprecipitated with Pygo2 specific antiserum, while pre-immune serum was used as 
a negative control using MCF-7 cell whole cell extracts (Figure 3.1A). Conversely, 
Pygo2 was detected in complexes immunoprecipitated using anti-Treacle antibodies 
(Figure 3.1B).  
Since Pol I recruitment to the rDNA genes requires multiple factors including 
Treacle and UBF-1 (Prieto & McStay, 2007), I tested whether Pygo2 interacted with  
UBF-1. Similar to Treacle, endogenous UBF-1 was detected in complexes 
immunoprecipitated using Pygo2 antibodies, but not with control IgG (Figure 3.1C). 
Conversely, Pygo2 was detected in complexes immunoprecipitated by UBF-1 antibodies 
(Figure 3.1D).  
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Figure 3.1. Pygo2 protein interacts with the nucleolar factors Treacle and UBF-1. 
(A) Endogenous protein complexes from MCF-7 cell extracts were immunoprecipitated 
using Pygo2 (Pygo2) antiserum or pre-immune serum, immunoblotting was performed 
with anti-Treacle antibodies. (B) Immunoprecipitations were performed with chicken 
anti-Treacle antibodies or normal chicken IgY or no antibody (-Ab), immunoblotting was 
performed with anti-Pygo2 antisera. The asterisk indicates a nonspecific protein 
associated with normal chicken IgY, which is not present in the control 
immunoprecipitation without antibody (-Ab). (C) Immunoprecipitations were performed 
using normal IgG or antibodies against Pygo2 from MCF-7 cell extracts and 
immunoblotted for UBF-1. (D) Reverse immunoprecipitations were performed using 
either normal IgG or antibodies against UBF-1 and blots were probed with anti-Pygo2 
antibodies. All input lanes represent approximately 2% of the total extract.  
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Initially, to ask whether Pygo2 protein was expressed in nuclei, sucrose density 
gradient centrifugation was performed to enrich both nuclear and nucleolar fractions from 
HeLa cells (Figure 3.2). Consistent with its observed interaction with Treacle and UBF-1, 
Pygo2 protein was detected in the enriched nucleolar fraction along with two other well-
described nucleolar proteins, UBF-1 and Fibrillarin. To examine the relative purity of the 
enriched fractions, blots were also probed with -actin as a control for the nuclear 
fraction but not the nucleolar fraction (Visa & Percipalle, 2010), while -tubulin was 
used as a control which was only present in the whole cell extract, but was not detected 
the nuclear or nucleolar fractions. 
Next, to examine the subcellular localization of Pygo2, indirect co-
immunofluorescence was performed for Pygo2 and Treacle (Figure 3.3) in several cancer 
cell lines. Expression of Pygo2 and Treacle was first examined in breast (MCF-7), 
cervical (HeLa) and ovarian (SkOv3) cancer cells (Figure 3.3A) and four prostate cancer 
cell lines (PC3, 22RV1, DU145 and LNCaP; Figure 3.3B). Treacle staining in green 
showed diffuse localization across the whole cell with strong punctate staining within the 
nucleus at the presumptive nucleoli. Pygo2, on the other hand, showed diffuse 
cytoplasmic staining in most cell lines, with distinct nuclear staining in Hela, SkOv3, 
22RV1, DU145 and LNCaP. All cell lines showed punctate nuclear staining of Pygo2  
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Figure 3.2. Pygo2 protein is detectable in nucleoli. Protein extracts from enriched 
nuclear and nucleolar fractions (phase contrast images of purified fractions on left) 
isolated on a sucrose gradient from HeLa cells were separated by SDS PAGE and 
compared to whole cell extracts. Immunoblots were performed using antibodies against 
Pygo2, UBF1 and B23. -actin was used as a negative control for nucleolar fraction and 
-tubulin was used as a negative control for both the nuclear and nucleolar fractions. 
Scale bar = 10 m.  
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Figure 3.3. Pygo2 co-localizes with Treacle in nucleoli. Confocal microscopy showing 
Pygo2 (red) co-localizes with Treacle (green) within the presumptive nucleoli of breast 
(MCF-7), cervical (HeLa) and ovarian (SKOV-1) cancer cells (A) and prostate cancer 
cells (PC3, 22RV1, DU145 and LNCaP; B). DAPI was used to stain DNA and 
differential interference contrast (DIC) was also used to visualize the cells in (B). Scale 
bar=20mm in (A) and scale bar=10mm in (B).  
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Figure 3.4. Pygo2 co-localizes with UBF-1 in nucleoli. Confocal microscopy showing 
Pygo2 (green) co-localizes with UBF-1 (red) within the nucleoli of breast (MCF-7), 
cervical (HeLa) and ovarian (SKOV-3) cancer cells (A) and prostate cancer cells (PC3, 
22RV1, DU145 and LNCaP; B). DAPI was used to stain DNA and differential 
interference contrast (DIC) was also used to visualize the cells in (B). Scale bar=20mm in 
(A) and scale bar=10mm in (B).  
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with some punctate spots overlapping with Treacle at the presumptive nucleoli. Similar 
patterns of staining were observed between Pygo2 and the nucleolar marker UBF-1 in  
breast, cervical and ovarian cancer cells (Figure 3.4A) and in prostate cancer cells (Figure 
3.4B). These results thereby suggest that at least a fraction of Pygo2 was present at 
nucleoli in cancer cells. While not shown here, staining was also observed in the primary 
prostate epithelial cell line PrEC, which showed a lower level of Pygo2 with diffuse 
staining throughout the nucleus.   
To assess whether Pygo2 localized to sites of newly synthesized 47S pre-rRNA at 
nucleoli, HeLa and SkOv3 cells were incubated with bromouridine triphosphate (Br-
UTP), which is incorporated into all cellular RNAs and highly expressed RNAs, such as 
rRNAs can be visualized by performing indirect immunofluorescence with an anti-
bromouridine antibody. As can be seen in Figure 3.5, Pygo2 co-localized with the newly 
synthesized rRNA at the nucleoli of both HeLa and SKOV-3 cells, therefore suggesting a 
possible association with de novo RNA synthesis. 
During mitosis, Nucleolar Organizing Regions (NORs) are transcriptionally 
silent, but are still bound by core components of the rDNA transcription machinery, such 
as UBF-1 (Heix et al, 1998; Roussel et al, 1996; Sirri et al, 1999). Staining of mitotic 
HeLa cells revealed that Pygo2 co-localized with UBF-1 at presumptive NORs during 
prophase, but then did not appear with NORs during metaphase and telophase, suggesting 
a transient or dynamic nucleolar association of Pygo2 during cell division (Figure 3.6). 
Therefore, the association of Pygo2 with nucleoli and newly synthesized rRNA likely 
occurs during interphase when a cell is growing in preparation for division. 
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Figure 3.5. Pygo2 is associated with nascent rRNA. HeLa and SKOV-3 cells were 
incubated for 10 minutes with BrUTP to observe newly synthesized RNA, fixed and 
stained for Pygo2 and BrUTP and visualized under confocal microscopy. Scale bar = 
10m.  
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Figure 3.6. Pygo2 dissociates from NORs during mitosis. Images show representative 
HeLa cells in prophase (pro), metaphase (meta) and telophase (telo). Proteins were 
detected with antibodies against: Pygo2 (green), UBF-1 (red). DAPI was used to stain 
DNA (blue). Arrows indicate co-localization between Pygo2 and UBF-1 in prophase.  
Scale bar = 5 m.  
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3.3.2 Pygo2 is dissociated from core transcriptional rDNA components in 
actinomycin D treated cells 
Production of the 47S pre-rRNA transcript is followed by its immediate post-
transcriptional processing via methylation and pseudouridylation required for maturation 
and cleavage into the 28S, 18S and 5.8S rRNA subunits. Transcription and processing of 
the 47S pre-rRNA occurs in distinct nucleolar compartments. To examine this, the Pol I 
inhibitor, actinomycin D (AMD) was used to disrupt 47S rDNA transcription (Figure 
3.7A) and the subcellular localization of Pygo2 was examined. At low concentrations, 
AMD inhibits actively transcribing rDNA transcriptional complexes and reversibly re-
organizes nucleoli according to their functional compartments: the fibrillar centers (FC), 
composed of the tandemly arrayed rDNA genes, the dense fibrillar component (DFC) and 
the granular component (GC), which contains rRNA undergoing post-transcriptional 
modification. This is observed by a restructuring of the FCs and DFCs into “nucleolar 
caps”, which appear as small blebs situated on the central body whose composition is 
assumed to be derived from the GC (Shav-Tal et al, 2005). 
In control, ethanol treated HeLa cells, UBF-1 (Figure 3.7B) and Treacle (Figure 
3.7C) co-localized with Pygo2 in overlapping regions of the nucleoli. Fibrillarin is a 
component of small nucleolar ribonucleoprotein complexes (snoRNP) that methylate 47S 
pre-RNA in a sequence-dependent manner (Reichow et al, 2007). B23 is a nucleolar 
stress sensor required for downstream rRNA processing (Yao et al, 2010). In control 
ethanol treated cells Pygo2 was detected in regions of the nucleolus with Fibrillarin 
(Figure 3.7D) and B23 (Figure 3.7E). These observations place Pygo2 in the nucleolus 
along with components of the core transcription machinery and the components involved  
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Figure 3.7. Pygo2 is localized to the nucleolus and to the central nucleolar body in 
cells treated with actinomycin D (AMD). (A) HeLa cells were treated with 
Actinomycin D for the indicated times in minutes or with solvent alone (EtOH) for 120 
minutes. RT-PCR was performed to examine 47S rRNA expression and equal loading 
was confirmed by examining expression of the RNA Pol II transcribed gene: Acidic 
ribosomal phosphoprotein P0 (ARPP-P0). (B-E) HeLa cells were treated with EtOH or 
with Actinomycin D (AMD) for 120 minutes, fixed and co-stained with antibodies 
against Pygo2 and the nucleolar markers UBF-1 (B), Treacle (C), Fibrillarin (D) or B23 
(E). Scale bar = 10m.  
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in post-transcriptional processing. In AMD treated cells, Pygo2 was found mainly in the 
central body, while UBF-1 (Figure 3.7A) and Treacle (Figure 3.7B) localized to the 
outer nucleolar caps, Fibrillarin was localized to the inner nucleolar caps (Figure 3.7C) 
and B23 was detected in the nucleoplasm (Figure 3.7D). While Pygo2 was not associated 
with nucleolar caps, it continued to remain closely associated with the nucleolus after 
AMD treatment, suggesting it is not likely a core component of the rDNA transcription 
machinery. 
3.3.3 Pygo2 binds to rDNA promoter chromatin 
The above observations suggested that Pygo2 is not associated tightly enough 
with the core complexes to withstand the effects of AMD, even though they co-
immunoprecipitated from cells. This is perhaps not surprising as Pygo2 has no DNA 
binding ability, yet it might still indirectly interact with the promoter through the core 
complexes, therefore this possibility was tested using chromatin immunoprecipitation 
(ChIP) assays. Sheared chromatin from HeLa cells was immunoprecipitated using 
RPA194 (the large subunit of RNA polymerase I), UBF-1, Treacle, -catenin and Pygo2 
antibodies and then subjected to PCR using oligonucleotide pairs complementary to the 
start of transcription on the rDNA promoter (rDNApro; Figure 3.8A). RPA194, UBF-1, 
Treacle and Pygo2 immunoprecipitates all contained promoter sequences but not control, 
internal transcribed sequence 1 (ITS-1; Figure 3.8B). Furthermore, while re-ChIP 
analysis confirmed the presence of all four proteins at the same region of the rDNA 
promoter (Figure 3.8C), Pygo2 interacted only with Treacle and UBF-1, but not with Pol 
I or proteins involved in transcript processing (Figure 3.8D).  
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Figure 3.8. Pygo2 is associated with the active rDNA transcription complex in vivo. 
(A) Genomic structure of human rDNA repeat indicating regions a, and b corresponding 
to rDNA promoter and ITS1 regions amplified by sequence-specific primers in chromatin 
immunoprecipitation assays. The 5’ and 3’ externally transcribed sequences (ETS), the 
internal transcribed sequences (ITS1 and 2) and the 18S, 5.8s and 28S rRNA subunits 
that are cleaved from the transcribed 47S precursor are indicated. (B) Chromatin 
immunoprecipitations from HeLa and SKOV-3 cells using antibodies against RPA194 
(RNA Pol I large fragment), UBF-1, Treacle and Pygo2. IgG from rabbit (IgG r) and 
mouse (IgG m) were used as negative controls. Oligonucleotide primers specific to 
amplify regions include sequences immediately upstream of the start of transcription 
(rDNA pro) and the internally transcribed sequence (ITS-1) as a negative control, as 
indicated in A. (C) Samples were subject to a first round of ChIP using Pygo2 antibodies 
and then subjected to a second round of Chip (re-ChIP) with the indicated antibodies. 
PCR was performed using primers against the rDNA core promoter. (D) Complexes 
containing Pygo2 were immunoprecipitated and probed for the nucleolar markers: 
Treacle and UBF-1, which are components of the rDNA transcription complex and B23, 
Fibrillarin and Nop56, which are components of the rRNA processing machinery, as well 
as the large subunit of RNA polymerase I (RPA194).  
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In separate experiments, the rDNA specific primers did not amplify sequence 
from chromatin precipitated by -catenin antibodies (Figure 3.9A). Furthermore, while  
active -catenin was readily detectable at the Wnt response element of the Axin2 
promoter upon LiCl treatment of HeLa cells (p<0.001), it was not detectable at the rDNA 
promoter (p=NS; Figure 3.9B). Finally, an interaction between -catenin and UBF in 
vitro was not observed (Figure 3.9C). Thus, while Pygo is typically associated with the 
canonical Wnt transcription complex, it did not appear to rely on -catenin for its 
localization to rDNA promoters. 
3.3.4 Pygo2 is not sufficient for rRNA expression in HeLa cells 
 Initially, to test whether Pygo2 was sufficient to drive transcription of the 47S 
pre-rRNA, Pygo2 was overexpressed in HeLa cells which were pulsed with 
3
H-uridine to 
label the all the rRNA species (Figure 3.10; top panel). Immunoblots were performed to 
confirm the expression of Pygo2 protein (Figure 3.10; bottom panel). Expression of wild-
type Pygo2 was not sufficient to drive or change the rRNA expression. However, 
overexpression of a Pygo2 mutant that was previously shown to be required for the 
transcriptional activity of the Pygo2 NHD (NPF-AAA; Städeli & Basler, 2005), resulted 
in a reduction in the production of all rRNA species. These results suggested that Pygo2 
(NPF-AAA) may possibly act as a dominant negative, thus interfering with rRNA 
transcription. Finally, a Bcl-9 binding mutant of Pygo2 (L369A) was not sufficient to 
drive or change the rRNA expression, further suggesting that the possible role of Pygo2 
at the rDNA transcription complex does not rely on Bcl-9/-catenin. 
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Figure 3.9. -catenin does not interact with the rDNA promoter in vivo. (A) 
Chromatin was prepared from HeLa cells and subjected to immunoprecipitation with 
negative controls (mock, -Ab, IgG, IgY, preimmune and anti-GST), positive controls 
(UBF-1 and Treacle), Pygo2 and -catenin. PCR was performed on the rDNA promoter 
and ITS-1 sequences. (B) Transcriptionally active -catenin does not interact with the 
rDNA promoter. HeLa cells were treated with either 20mM NaCl or 20mM LiCl, RNA 
and chromatin were extracted after four hours as described. qPCR was performed to 
assess the relative activation of Axin2 mRNA expression induced by LiCl (left panel; 
p<0.0001). ChIP analysis was performed to examine the relative amounts of -catenin 
binding to both the Axin2 Wnt responsive element (WRE) and to the rDNA promoter 
(right panels) Primer sequences have been described elsewhere [1]. Error bars represent 
standard deviation of three independent experiments. (***p<0.001, NS; not significant; 
C) UBF-1 interacts with the Pygo2 PHD domain, but not -catenin in vitro. GST fusion 
proteins of -catenin and Pygo2 PHD domain were used in an in vitro pulldown assay 
along with radiolabeled UBF-1 (top panel). Gels were stained with coomassie blue to 
visualize relative amounts of GST proteins (bottom panel).  
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Figure 3.10. Pygo2 overexpression is not sufficient to increase de novo rRNA 
transcription. Hela cells were transfected with pCS2 (EV; lane 1), pCS2-full length 
Pygo2 (Pygo2 wt; lane 2), pCS2-Pygo2 NPF-AAA (Pygo2 NPF mut; lane 3), pCS2-
Pygo2 L369A (Bcl9 binding mutant; lane 4) and assayed for de novo rRNA synthesis by 
3
H-uridine incorporation (
3
H-uridine; upper panel). Major rRNA species are indicated 
and relative levels of 28S and 18S rRNAs were assessed by ethidium bromide staining 
(Etbr; middle panel). Expression of Pygo2 protein was confirmed by immunoblotting for 
Pygo2 (IB; lower panel), -actin was used as a loading control.  
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3.3.5 Pygo2 recruits histone acetyltransferase activity to the rDNA promoter 
Pygopus was previously shown, through binding of its PHD to H3K4me3 marks, 
to recruit histone acetyltransferase activity to its conserved NHD at active Wnt target 
genes (Fiedler et al, 2008; Gu et al, 2009; Andrews et al, 2009; Chen et al, 2010). Pygo2 
was present at the rDNA promoter (Figure 3.8) but overexpression was not sufficient to 
increase rRNA transcription, however an NHD mutant of Pygo2 (NFP-AAA; Figure 
3.10) interfered with rRNA transcription, suggesting that Pygo2 may be required for 
transcription of the 47S precursor rRNA. Therefore, to address a possible requirement of 
endogenous Pygo2 in rRNA transcription, two Pygo2-targeting siRNAs were selected for 
loss-of-function studies. First, to test the specificity of the Pygo2 siRNAs, knockdowns 
were performed in which Pygo2 cDNA was co-expressed and expression of the 
previously identified Pygo2 responsive gene p21 was analyzed (Gu et al, 2009). 
Transfection of two Pygo2-targeting siRNAs resulted in an increase in p21 expression, as 
was previously shown. Co-transfection of the Pygo2 cDNA with one of the siRNAs that 
targeted the 3’-UTR (hpy2-X) of Pygo2, restored the levels of p21 present in the control 
(NTC + pCS2), verifying the specificity of the knockdown (Figure 3.11A). Depletion of 
Pygo2 using RNAi also clearly reduced the levels of nucleolar Pygo2 (Figure 3.11B).  
Next, I tested whether Pygo2 loss-of-function affected histone modifications at 
the rDNA promoter by ChIP-quantitative (q) PCR. Transfection of Pygo2 siRNA reduced 
the amount of Pygo2 bound to the rDNA promoter to approximately 41% compared to 
the NTC siRNA (Figure 3.12A; p<0.01). There was no effect on acetyl (Ac) H3 levels 
and while not statistically significant (NS; p=0.1), there was a detectable increase in 
H3K4me3 levels at the rDNA promoter, despite a slight decrease in the global levels of  
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Figure 3.11. Confirmation of Pygo2 siRNA specificity. (A) Knockdown of Pygo2 
results in increased levels p21, while co-expression of Pygo2 restored levels of p21. 
Human endocervical cancer cells were transfected with empty plasmid (pCS2) with either 
non-targeting (NTC), hPy2-X (targeting 3’untranslated region) or hPy2-Z (targeting 
coding region) siRNAs. Rescuing Pygo2 cDNA (pCS2-hPygo2) was co-transfected with 
NTC and hPy2-X (targeting 3’untranslated region) siRNAs. Blots were probed with -
actin to confirm equal loading. (B) Knockdown of Pygo2 reduces detectable nucleolar 
Pygo2 protein.  HeLa cells were either mock transfected, or transfected with NTC, hpy2-
X or hpy2-Z siRNAs. Cells were then fixed 48 hours later and stained with antibodies 
against Pygo2 (green) and UBF-1 (red). DAPI was used to stain DNA (blue). Scale bar = 
20 m.  
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Figure 3.12. Pygo2 depletion decreases histone H4 acetylation at the rDNA 
promoter. (A) Pygo2 plays a role in H4 acetylation at the rDNA promoter. ChIP-qPCR 
analysis of HeLa cells treated with NTC (siNTC) and Pygo2 (siHPY2) siRNAs showing 
rDNA promoter occupancy relative to the input chromatin. (B) HeLa cells were 
transfected NTC, hpy2-X and hpy2-Z siRNAs and assayed for de novo rRNA synthesis 
by 
3
H-uridine incorporation (
3
H-uridine; upper panel). Positions of the major rRNA 
species are indicated on the right and relative levels of 28S and 18S rRNAs were assessed 
by ethidium bromide staining (Etbr; middle panel). (C) Transfection of siRNAs targeting 
Pygo2 and Treacle reduced transcription from an rDNA promoter reporter. HeLa cells 
were treated with transfection reagent alone (Mock), NTC, or siRNAs targeting either 
Pygo2 (X, Z) or TCOF-1 mRNAs (siTreacle). After 48 hours, the cells were transfected 
with an rDNA luciferase reporter (pHrD-IRES-LUC). Relative luciferase units were 
normalized to -galactosidase activity. All data are represented as mean +/- SD from 
three independent experiments. (**p<0.01, ****p<0.0001, NS; not significant) 
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H3K4me3 (Figure 3.13A), possibly reflecting a compensatory mechanism for Pygo2 
recruitment. Notably, Pygo2 knockdown reduced acetyl histone-H4 levels occupying the  
promoter region to approximately 47% compared to the NTC siRNA (p<0.01) but did not 
significantly affect the binding of complex(es) containing Pol I or UBF (p=NS; Figure 
3.12A). Like H3K4me3, there was a detectable decrease in global levels of acetyl-H4 
with Pygo2 siRNA treatment, but this was also accompanied by a decrease in H4 protein 
as well (Figure 3.13B), consistent with an observed role for Pygo2 in histone gene 
expression (Gu et al, 2012). Thus, while Pygo2 was not necessary for recruitment of 
transcriptional components, it appeared to be required to maintain acetylation of 
associated histones at the promoter during rDNA transcription. 
To test whether the observed reduction of acetyl-H4 at the rDNA promoter 
influenced rRNA transcription, further loss of function experiments were performed. 
Pygo2 knockdown resulted in reductions in the 32S, 28S and 18S rRNAs as measured 
by
3
H-Uridine (Figure 3.12B) incorporation. Similarly, knockdown of Pygo2 significantly 
reduced transcription from a transfected luciferase reporter gene under the control of the 
rDNA promoter (pHrD-IRES-Luc; Figure 3.12C). To further confirm and quantitatively 
assess the transcription of the 47S precursor rRNA, qPCR was performed on Pygo2 
siRNA treated cells. Treatment of both HeLa (Figure 3.14A) and SKOV-3 (Figure 3.14B) 
cells with Pygo2 siRNA showed a significant reduction Pygo2 mRNA levels (p<0.001) 
as well as a significant reduction in the levels of the 47S rRNA (p<0.01). Together, these 
observations provided evidence that Pygo2 is involved in transcription of the 47S pre-
rRNA by maintaining levels of acetyl-H4. 
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Figure 3.13. Depletion of Pygo2 results in a reduction of H3K4me3, H4 and 
acetylated H4 levels. (A) Assessment of global levels of H3K4me3 following Pygo2 
knockdown using a non-targeting siRNA (siNTC) and two Pygo2 siRNAs (hPy2-X and 
hPy2-Z), demonstrating a reduction of H3K4me3. (B) Assessment of global levels of 
histone H4 and acetylated histone H4 levels following Pygo2 knockdown. Results 
demonstrate a reduction in both histone H4 and acetylated H4, relative to histone H3 
levels. Relative densitometric values relative to H3 are given in parenthesis for (A) and 
(B).  
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Figure 3.14. Pygo2 depletion resulted in a reduction of 47S pre-rRNA independent 
of p53. (A) p53 independent reduction of the 47S pre-rRNA by Pygo2 knockdown. HeLa 
cells were treated with either NTC or Pygo2 siRNAs alone or in combination with p53 
siRNAs. RT-qPCR was performed and relative levels of Pygo2, p21 and 47S mRNAs are 
shown. (B) RT-qPCR was performed using RNA collected from p53-null SKOV-3 cells 
treated with NTC and Pygo2 specific siRNAs. Relative expression levels of Pygo2, 47S 
and p21 mRNAs were calculated as percentages of the NTC control.  
Data are represented as mean +/- SD of three independent experiments. (****p<0.0001, 
***p<0.001, **p<0.01, NS; not significant)  
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3.3.6 Depletion of Pygo2 resulted in growth arrest by activation of the RP-Mdm2-
p53 nucleolar stress response in HeLa cells 
Nucleolar stress-induced cell cycle arrest is caused by disruptions in ribosome 
biogenesis resulting in the association of unincorporated ribosomal proteins, such as 
ribosomal protein (RP) L11, with the E3 ubiquitin ligase HDM2, thereby compromising  
its ability to inhibit p53 tumor suppressor and apoptotic function (Lohrum et al, 2003). I 
therefore hypothesized that disruption of rDNA transcription by depletion of Pygo2 could 
possibly trigger the nucleolar stress response. 
Notably, it could be argued that the attenuation in rDNA transcription in response 
to treatment with Pygo2 siRNA was a secondary effect subsequent to disruption of cell 
cycle progression due to an upregulation of p53. To test this possibility, I first determined 
the effect of reducing both proteins on rRNA production using both Pygo2 and p53 
siRNAs. Depletion of Pygo2 alone resulted in a decrease of 47S rRNA and an increase of 
p21 (Figure 3.14A). Co-transfection with both Pygo2 and p53 siRNAs resulted in a 
decrease in the p53 target gene p21 as expected. It did not, however, restore levels of 47S 
rRNA (Figure 3.14A), suggesting that the reduction in 47S rRNA by Pygo2 depletion 
was independent of p53 stabilization and activation. 
Next, to test whether the observed increase in p53 by depletion of Pygo2 resulted 
from activation of the nucleolar stress response pathway (Zhang & Lu, 2009), HDM2 
was immunoprecipitated from cells treated with Pygo2 siRNAs and the interaction 
between HDM2 and RPL11 was assessed. In cells treated with Pygo2 siRNA, RPL11 
interacted with HDM2, while in untreated (mock) and control (siNTC) siRNA treated 
cells no interaction between RPL11 and HDM2 could be detected (Figure 3.15A, upper  
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Figure 3.15. Pygo2 depletion results in activation of the nucleolar stress response. 
(A) HDM2 interacted with RPL11 in Pygo2-depleted HeLa cells. Cells were treated with 
reagent alone (Mock), NTC siRNA (siNTC) or hpy2-X siRNA (siHPY2) and extracts 
were subject to immunoprecipitation (IP) with an antibody against HDM2. Blots were 
probed with HDM2 and RPL11 antibodies (top panel). Inputs (5%) were probed with 
antibodies against HDM2 (relative band densities in parenthesis), RPL11, Pygo2 and the 
loading control, -actin (bottom panel). (B) HeLa cells were treated with either NTC or 
Pygo2 siRNA alone and in combination with p53 siRNA. FACS analysis was then 
performed to show the percentage of cells in each phase of the cell cycle. Treatment of 
cells with hpy2-X or with hpy2-Z resulted in significant increases in the proportion of 
cells in G1 compared to the NTC siRNA. Co-treatment of cells with p53 siRNA plus 
hpy2-X or with p53 siRNA plus hpy2-Z showed no significant increase in the proportion 
of cells in G1 compared to p53 plus NTC siRNAs. Data are represented as mean +/- SD 
of three independent experiments. (**p<0.01, NS; not significant; C) Knockdown of p53 
restored cell cycle progression protein expression in cells depleted of Pygo2. Cells were 
treated with NTC, or Pygo2 siRNAs (X, Z), with or without p53 siRNA. G1 markers 
include p53 and p21, G2/M markers include p-cdc2 (Y-15), Cyclin A, Cyclin B1. -actin 
was used as a loading control.  
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panel). Interestingly, there was an increase in HDM2 levels in Pygo2-depleted cells 
(Figure 3.15A, “Input”), which was consistent with previous findings demonstrating  
HDM2 as a transcriptional target of p53 (Barak et al, 1993). The binding of RPL11 to 
HDM2 suggest that upon depletion of Pygo2, the nucleolar stress pathway was activated. 
The increase in p53 levels following Pygo2 knockdown was correlated with cell 
cycle arrest and a significant increase in the number of cells at G1 (p<0.01), accompanied 
by a decrease in the number of cells at G2/M (p<0.01), compared to the NTC siRNA 
alone (Figure 3.15B). On the other hand, co-depletion Pygo2 and p53 resulted in a rescue 
of cell growth arrest mediated by Pygo2 depletion, suggesting the growth arrest was p53 
dependent (Figure 3.15B; p=NS). Alone, Pygo2 siRNA increased both p53, and the p53 
target gene p21 but reduced the levels of the G2/M markers phospho-cdc2, Cyclin A and 
Cyclin B1 (Figure 3.15C). In contrast, co-depletion of Pygo2 and p53 reduced p21 
expression and restored the cell-cycle progression markers phospho-cdc2, Cyclin A and 
Cyclin B (Figure 3.15C). Together, these results suggested that Pygo2 depletion resulted 
in the accumulation of p53 and subsequent arrest at G1, consistent with activation of the 
nucleolar stress response. 
3.3.7 Pygo2 knockdown reduced rRNA transcription in p53-null SkOv3 cells 
The above-mentioned experiments indicated that while co-transfection of Pygo2 
and p53 siRNAs had little effect on cell cycle progression, there was a persistent 
reduction of 47S rRNA transcription. Therefore, to corroborate this data, Pygo2 depletion 
was performed in the p53-null ovarian cancer cell line, SKOV-3 (Figure 3.16). 
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Figure 3.16. Depletion of Pygo2 causes SKOV-3 cells to accumulate in G2/M. (A) 
FACS analysis of SKOV-3 cells transfected with NTC and Pygo2 siRNAs. Data are 
represented as mean +/- SD of three independent experiments. (*p<0.05; B) Immunoblot 
analysis of SKOV-3 cells transfected with NTC and Pygo2 specific siRNAs. HeLa cell 
extracts were used as a p53-positive control. G1 markers include p53 and p21, G2/M 
markers include p-cdc2 (Y-15), Cyclin A, Cyclin B1. Relative Cyclin A band densities 
given in parenthesis. -actin was used as a loading control.  
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Depletion of Pygo2 in SKOV-3 cells, which we previously demonstrated was sensitive to 
knockdown of Pygo2 (Popadiuk et al, 2006), also caused a significant decrease in 47S 
rRNA (Figure 3.14B). However, cell cycle analysis of Pygo2 depleted SKOV-3 revealed 
an accumulation of cells in the G2/M phase (Figure 3.16A; p<0.05). The only cell cycle 
marker examined with a detectable change after Pygo2 depletion was Cyclin A, which 
was consistent with the observed cell cycle arrest at G2/M (Figure 3.16B). It is unclear 
whether G2/M arrest in p53-null cells was the result of a nucleolar stress response similar 
to that of p53-positive cells. These observations suggested that a primary effect of Pygo2 
depletion was on rRNA production, leading to a subsequent negative effect on cell cycle 
progression, providing evidence linking Pygo2 function to rDNA transcription.  
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3.4 Discussion  
The association of Pygo2 with ribosomal gene promoters and its participation in 
rRNA transcription, suggests a function for Pygo2 in ribosomal biogenesis required for 
proliferative growth. In addition to its demonstrated role in canonical Wnt signalling, I 
hypothesize that Pygo2 plays a role in ribosomal gene transcription specifically through 
its previously identified role, the acetylation of histone H4 ( Figure 3.12; Andrews et al, 
2009), but at the rDNA gene promoter in lieu of, or more likely in addition to, Wnt target 
gene promoters/enhancers. This step would seemingly maintain requisite levels of 47S 
precursor rRNA, necessary for cell division, and without which would lead to cell growth 
arrest. 
Our data incorporates Pygo2 into models of active ribosomal gene transcription 
(Denissov et al, 2011), perhaps as an adaptor protein for epigenetic modifiers required for 
histone acetylation (Figure 3.17). I propose that Pygo2 is present at the rDNA promoter 
through its interaction with both UBF-1 and Treacle. However, the relatively small 
proportion of the total Pygo2 protein observed in complex with UBF-1 and Treacle 
suggest that this may not be the primary transcriptional target of Pygo2, hence, these 
observations will be further discussed in Chapter 4. The fact that Pygo2 does not make 
direct contact with Pol I is consistent with the idea that Pygo2 functions largely as an 
adaptor protein, required to induce or promote epigenetic modifications to augment 
transcription. It is possible that its recruitment to active sites or ribosomal gene 
transcription and may also depend on H3K4 methylation status at the vicinity of rDNA 
promoters.   
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Figure 3.17. Proposed role of Pygopus in ribosomal DNA transcription. Pygopus is 
required for chromatin remodeling associated with ribosomal gene transcription. The 
PHD of Pygo (green) binds directly to H3K4me3 histone marks associated with active 
gene promoters, allowing the recruitment of histone acetyltransferases (HAT) by its NHD 
to the rRNA transcriptional complex through its interaction with Treacle (TCOF-1), a 
large phosphoprotein that may serve as a scaffolding function to recruit Pygo2 to the 
rDNA promoter vicinity. The resulting H4 acetylation, a prerequisite for nucleosomal 
decondensation and promoter demethylation, is required for transcription of the 47S 
precursor rRNA by RNA Pol I. For simplicity, not all proteins involved in complex 
formation are shown.  
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The diverse requirements for Pygo2 in development suggest that its cellular 
function is context dependent, as demonstrated by pygo loss-of-function studies in mice. 
Transgenic animals deficient for mPygo2 die as neonates but display a range of tissue and 
organ defects, some of which, such as in kidney and mammary gland morphogenesis, 
have been identified as canonical Wnt-dependent (Li et al, 2004, 2007a; Schwab et al, 
2007). However, the requirement for mpygo2 in lens formation along with other 
unattributed defects, such as overall growth agenesis and craniofacial defects including 
cleft palate was demonstrated as Wnt-independent (Song et al, 2007). These observations 
are consistent with the craniofacial and cleft palate defects observed in a mouse model of 
Treacher-Collins Syndrome (Sakai & Trainor, 2009) and may possibly be explained by a 
cooperative role for Treacle and Pygo2 in ribosome biogenesis.  
 Knock-down of Pygo2 in different cell lines revealed a consistent requirement for 
rRNA transcription, the cellular responses in different cell lines were strikingly different 
and appeared to be largely dependent on the tumor suppressor p53. I hypothesize that 
depletion of Pygo2 results in a p53 dependent cell cycle arrest in G1 in cells that express 
wild-type p53. Consistently, this was confirmed in other p53 positive cell types, 
including human endocervical cells, as shown above (Figure 3.11A). When both Pygo2 
and p53 were co-depleted in HeLa cells, there were no apparent changes in the 
proportions of cells in each phase of the cell cycle compared to control treated cells 
(Figure 3.15), suggesting the observed G1 arrest was p53 dependent. While not explored 
here, co-depletion of Pygo2 and p53 could possibly result in changes in the relative 
growth rates, which would be consistent with the observed reduction in 47S rRNA 
transcription (Figure3.14A). Depletion of Pygo2 in the p53 null SKOV-3 cell line (along 
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with other p53 null cell lines, such as the prostate cell line PC3, data not shown), resulted 
in an accumulation of cells in the G2/M phase of the cell cycle (Figure 3.16A). This is a 
result that is surprising considering the co-depletion of Pygo2 and p53 in HeLa cells 
resulted in no apparent cell cycle arrest. While there was a decrease in the levels of the 
47S pre-rRNA in SKOV-3 cells, I’m not certain that the accumulation of cells in G2/M 
can be entirely explained by this result. I therefore propose that the accumulation of cells 
in G2/M is at least partly due to an unknown role of Pygo2, as will be discussed in 
Chapter 4. 
 In support of my hypothesis that Pygo2 has an important function in ribosomal 
RNA transcription are the observations that depletion of Pygo2 triggered the nucleolar 
stress response, which could be reversed by knocking down p53, mirroring results found 
in a Treacle knock-out mouse model for Treacher-Collins syndrome (Dixon et al, 1997; 
Jones et al, 2008). The parallel between a requirement for Treacle-dependent ribosome 
biogenesis in normal development and Pygo2-dependent ribosome biogenesis in cancer 
cells suggests that the interaction we observed between Pygo2 and Treacle may be a 
conserved adaptation to rapid cell proliferation. Therefore, it would be interesting to 
examine the role of Treacle in a cancer cell model. 
 While Pygo2 is required for rRNA transcription, overexpression of Pygo2 was not 
sufficient to increase rRNA transcription in HeLa cells (Figure 3.10). One possible 
explanation for this could be that Pygo2 protein in HeLa cells is highly expressed 
(Andrews et al, 2008). Alternate possibilities may include scenarios which are not 
dependent on Pygo2 levels but on the levels and activities of additional factors. For 
example, Pygo2 activity could be tightly controlled and/or additional transcriptional 
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regulatory proteins may be present in limited amounts. Therefore, additional exogenously 
expressed Pygo2 in these cells may not result in a detectable increase in rRNA 
transcription. Although not explored here, overexpression of Pygo2 in a low expressing 
Pygo2 cell line, such as a normal or primary cell type, could possibly render a detectable 
increase in rRNA transcription. Interestingly, overexpression of a NPF-AAA Pygo2 
mutant lacking transcriptional activity when tethered to DNA using a GAL4 DNA 
binding domain (Städeli & Basler, 2005), resulted in a significant reduction in rRNA 
transcription (Figure 3.10). These results indicate that the NPF residues of Pygo2 are 
indeed important for mediating interactions necessary for its role in rRNA transcription 
and thereby suggest that the transcriptional activity of Pygo2, in addition to its chromatin 
effector function is likely important for its role in rRNA transcription. 
The core components of the rDNA transcriptional machinery localize to nucleolar 
caps following AMD treatment (Shav-Tal et al, 2005). The localization of Pygo2 to the 
central nucleolar body and not to nucleolar caps after treatment with AMD (Figure 3.7), 
is not inconsistent with a role in rDNA transcription. Similarly, p14/ARF, which plays a 
direct role in repressing rRNA transcription (Lessard et al, 2010), also co-localizes to the 
central nucleolar body following AMD treatment (Shav-Tal et al, 2005). While Pygo2 
and p14ARF are not likely core components of the rDNA transcription machinery, it is 
possible that as modifiers of the rRNA transcription complex they associate with the 
central nucleolar body following AMD treatment. Finally, Pygo2 was dynamically 
associated with the active transcription complex required for rRNA transcription, two 
observations that are relevant to this are: 1) Pygo is not localized to nucleolar caps after 
AMD treatment, but is still associated with the nucleolus. 2) Pygo does not co-localize 
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with UBF at NORs during mitosis, when transcription is silenced (Heix et al, 1998; 
Roussel et al, 1996; Sirri et al, 1999), but appeared to be associated with the nucleolus 
during interphase. 
 The increased demand for ribosomes in cellular growth and proliferation requires 
that both RP and rRNA synthesis be amplified and precisely coordinated. Pygo2 may 
serve in this respect to augment or maintain Pol I-dependent transcription to keep in 
stride with ribosomal protein production in proliferating cells. Since Pygo2 is upregulated 
in a variety of cancers, these findings suggest that targeting Pygo2 with a small molecule 
inhibitor, for example JBC117 (Ali et al, 2016), represent a broadly applicable strategy 
would disrupt rDNA transcription, thereby targeting aberrantly growing cells.  
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Chapter 4: Transcriptional control of cell division by the Pygopus 
chromatin modulator  
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4.1 Introduction 
During mitosis, equivalent segregation of genetic material to two daughter cells is 
a precisely coordinated process and depends on mitotic spindle capture of chromosomes. 
Proper biorientation is required for chromosomal segregation and is thought to occur by a 
search and capture mechanism in which nucleating spindle microtubules emanate from 
the centrosomes and make bi-oriented, amphitelic attachments to sister kinetochores, the 
molecular scaffolds that form the major attachment site to the chromosomes (Monda & 
Cheeseman, 2015; Tanaka, 2013, 2010; Tanenbaum & Medema, 2010; Foley & Kapoor, 
2013). In addition to search and capture, other mechanisms efficiently drive biorientation. 
For example, the kinetochore contains nucleating microtubules that aid in microtubule-
kinetochore capture by a mechanism dependent upon microtubule associated TPX2 
(Katayama et al, 2008). Another major driver of microtubule-kinetochore interaction and 
capture is the Regulator of Chromosome Condensation 1 (RCC1) mediated RanGTP 
concentration gradient that exists around mitotic chromosomes which promotes 
microtubule nucleation (Kalab & Heald, 2008). 
Mitotic spindle formation is controlled largely by the complex actions of several 
families of serine-threonine kinases that include, but are not limited to, both the Aurora 
Kinases (AurK) and the Polo-like kinases (Plk). AurKA is associated with mitotic entry, 
centrosome maturation and mitotic spindle assembly (Carmena et al, 2009). AurKB is the 
catalytic component of the chromosomal passenger complex (CPC) that acts as a master 
regulator of mitosis at many different levels, including chromosome condensation, 
kinetochore-microtubule attachments, spindle assembly checkpoint (SAC) activation and 
cytokinesis (Carmena et al, 2012). The Plks are required for several different mitotic 
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events, such as centrosome and kinetochore maturation, spindle assembly and cytokinesis 
(Archambault et al, 2015). Finally, both AurK and Plk are active in cancer and have 
gained attention as therapeutic targets (Goldenson & Crispino, 2014; Degenhardt & 
Lampkin, 2010). 
Pygo2 is an emerging target in malignancy since its elevated expression and 
requirement for growth has been demonstrated in a number of different cancers (Andrews 
et al, 2007; Popadiuk et al, 2006; Tzenov et al, 2013; Zhang et al, 2015a; Liu et al, 
2013). In addition to its role in Wnt signalling, Pygo2 protein acts broadly as a chromatin 
effector, linking active H3K4me3 marks to euchromatin formation through its association 
with histone acetyltransferase activity (Andrews et al, 2009; Chen et al, 2010; Fiedler et 
al, 2008), especially for expression of highly transcribed RNAs, such as histone mRNAs 
and ribosomal RNAs, essential for DNA replication and cell cycle progression (Gu et al, 
2012; Andrews et al, 2013). These observations raised the possibility that Pygo2 acts 
epigenetically as a “euchromatic switch” to promote the transcription of key genes 
required for deregulated cell growth and division, such as in mammary tumor initiation 
(Watanabe et al, 2013) and prostate cancer (Yang et al, 2013). Therefore, while the role 
of Pygo2 in cancer growth has been clearly demonstrated, its role in cell division is 
unknown. In this study, I show that Pygo2 is essential for the proliferation of cancer cells 
through its epigenetic involvement in a transcriptional program controlling genes directly 
required for mitosis. 
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4.2 Materials and methods 
4.2.1 Cell lines and antibodies 
SKOV-3, PC3 and HeLa S3 cells were obtained from the American Type Tissue 
Collection (ATCC) and were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum. Antibodies used are given in Table 4.1.  
4.2.2 RNAi and transfections 
Non-targeting (siNTC) and Pygo2 (siPy2) siRNAs (Table 4.2) and concentrations 
used were previously described (Andrews et al, 2013). siRNAs were transfected at 5nM 
for HeLa S3 and 20nM for PC3 and SKOV-3 cells using Lipofectamine RNAiMAX 
(Invitrogen), as per the manufacturers’ instructions.  
4.2.3 Immunoblotting and immunoflourescence 
Immunoblotting and immunoflourescence was performed exactly as described (Andrews 
et al, 2013). Confocal images were taken using a FluoView FV1000 confocal microscope 
(Olympus). For scoring of mitotic cells, three experiments were performed and cells 
counted from 5 random fields per treatment (siNTC, N=150; siPy2-1, N=196; siPy2-2, 
N=169) and were classified according to the observed mitotic profiles. Results represent 
averages for three experiments +/- SEM. P-values were calculated one-way ANOVA, 
using Tukey’s multiple comparison test. 
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Table 4.1. Antibodies. 
Antibody Clone/Catalogue 
number 
Company/Reference 
Normal rabbit IgG 12-370 Millipore 
-tubulin Ab15246 Abcam 
-tubulin DM1A Abcam 
-tubulin Ab11317 Abcam 
INCENP 58-217 Abcam 
H3K9Ac Ab10812 Abcam 
histone H3 Ab1791 Abcam 
H3K27Ac Ab4729 Abcam 
Aurora Kinase B Ab2254 Abcam 
Pygo2 S3I4 Tzenov et al., 2015 
Pygo2  Abe109 Millipore 
H3K4me3 07-473 Millipore 
H3K14Ac 07-353 Millipore 
Aurora Kinase A 1F8 Cell Signalling 
Technology 
Aurora Kinase A (P-
T288) 
C39D8 Cell Signalling 
Technology 
Survivin 71G4B7 Cell Signalling 
Technology 
Phospho-histone H3 06-570 Upstate Biotechnology 
-actin AC-15 Sigma Aldrich 
Flag M2 Sigma Aldrich 
FITC-CREST 15-235-F Antibodies Incorporated 
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Table 4.2. siRNA and oligonucleotide sequences. 
 
 
F-primer (5’=>3’) R-primer (5’=>3’) Reference 
Gene primer set    
-actin ATCTGGCACCACACCTTCTAC
AATGAGCTGCG 
ATGGCTGGGGTGTTGAAGGT
CTC 
(Andrews et 
al, 2013) 
Pygo2 GTCCCCCACTCCATGGCCGC
CTCG 
TCGCTTCTTTTCTGGACTCTT
C 
(Andrews et 
al, 2008)  
INCENP AAGCTCATGGAGTTTCTCTGC CGTCTCTTCTTCCGTCGGTTC HPB*** 
RCC1 CGGTGTGATTGGACTGTTGG
A 
CACCAAGTGGTCGTTTCCTG
A 
HPB 
CEP290 AGATGCTCACCGAACAAGTA
GA 
ATGAGTCTGTTGAGAAAGGG
TTG 
HPB 
BOD1 AGCCAGCTTACCAAAACCTG
A 
GCTTCCAACATCCCTGACTGA
A 
HPB 
HAUS8 GGTCGGAAAGGGTGACCTG GCGTCTTTTTGACGATGCTTT
TG 
HPB 
OIP5 TGAGAGGGCGATTGACCAAG AGCACTGCGTGACACTGTG HPB 
RAD51 CGAGCGTTCAACACAGACCA GTGGCACTGTCTACAATAAG
CA 
HPB 
TPX2 TCCTGCCCGAGTGACTAAGG 
 
CTGTTAGGGGTTCGTTTATGG
AA 
HPB 
ASPM GGCCCTAGACAACCCTAACG
A 
AGCTTGGTGTTTCAGAACATC
A 
HPB 
CDCA3 ACCTTGGAACCAGACTGAGT
T 
GGGATCTCCCTAGTACCTTG
CT 
HPB 
CKAP5 TGTGGAAAGCAAGGTTAAGT
GG 
ACTCTGGGCTCTTTTCATCCT HPB 
SMC3 ATTGGTGCCAAAAAGGATCA
GT 
GATTGCTTCGAGAAAAACCA
GC 
HPB 
CASC5 CTTCACACCGAGGACTCAAG
A 
TTTGATGTGTAGAAGAGGCA
CTG 
HPB 
BRCA1 ACCTTGGAACTGTGAGAACT
CT 
TCTTGATCTCCCACACTGCAA
TA 
HPB 
AURKA GAGGTCCAAAACGTGTTCTC
G 
ACAGGATGAGGTACACTGGT
TG 
HPB 
H4E CCGTAAGGTCCTGCGAGATA
A 
AGTCACAGCATCACGAATCA
C 
(Gu et al, 
2012) 
H4B AAGGCGGTAAAGGTTTGGGT
A 
GGAAATTCGCTTAACCCCAC
C 
(Gu et al, 
2012) 
p21 GATGTCCGTCAGAACCCATG
C 
CAAAGTCGAAGTTCCATCGCT
C 
(Andrews et 
al, 2013) 
KI67 AGAAGAAGTGGTGCTTCGGA
A 
AGTTTGCGTGGCCTGTACTAA HPB 
ChIP primer set    
INCENP 
promoter 
CCGCCTCTTAGTCCCGCAGA 
TTGC 
 
 
CTGAAGGCTCAGCCAATCCT
CG 
 
RCC1 promoter CTGCAGTAGATTCCCAGAAG 
CCTCAG 
 
GAAGCGACCACTGCGAATCT
GTCTCC 
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BOD1 promoter CAGATGGCGTCAACGTTGACCTT
TGC 
GCGATCACGAGGCCTGCGCCTAC
AGTTCC 
 
CEP290 
promoter 
GATTCTCCGCCGGAGTCCCAGAG
C 
CCTCCTCTTCTCAGGGACTTCAGT
TCC 
 
AURKA promoter GGAGTTAAACCCTCTAGCTAGAA
AGC 
GTTGGCTCCACCACTTCCGGGTTC 
 
 
siRNAs    
siNTC GGACUGUGGUCAACCAUGU
UU 
  
 
(Andrews et 
al, 2013) 
siPy2-1 GGAGACAGCUUUAGGGAAUU
U 
 
siPy2-2 GGAGUGAGGUGAACGAUGA
UU 
 
 
***HPB (Harvard primer bank) 
.  
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4.2.4 RT-qPCR and ChIP-qPCR 
RNA was extracted using the RNeasy kit (Qiagen) and was used to make cDNA 
using MMLV (Invitrogen), as per the manufacturers protocols. For RT-qPCR analysis, 
primers used are listed in Table 4.2 and reactions used RT2 SYBR Green master 
mix (Qiagen). Relative values were calculated using the 2
-ΔΔCt 
method normalized to -
actin expression. Briefly, ChIP was performed using nuclei collected from formaldehyde 
crosslinked HeLa S3 cells. Nuclei were extracted in RIPA buffer (1.1% triton X-100, 
0.01% SDS, 1.2mM EDTA, 16.7mM Tris pH8.1 and 167mM NaCl) supplemented with 
protease inhibitors and phenylmethanesulfonyl fluoride. DNA was sheared using a Sonic 
Dismembrator 100 (Fisher) to an average size of 300-500bp. Immunoprecipitations were 
performed using approximately 1mg of chromatin and 3g of antibody, preblocked 
protein A agarose beads (Millipore) were used to capture the antibody-protein-DNA 
complexes. Beads were washed three times in a low salt buffer (1.0% triton X-100, 0.1% 
SDS, 2mM EDTA, 20mM Tris pH 8.1, 150mM NaCl) followed by one wash in high salt 
buffer (1.0% triton X-100, 0.1% SDS, 2mM EDTA, 20mM Tris pH 8.1, 500mM NaCl) 
and one wash in TE buffer. Complexes were eluted in elution buffer (1.0% SDS and 
100mM NaHCO3); crosslinks were reversed at 65
o
C overnight. Samples were RNase A 
and proteinase K treated before purifying the DNA using the QIAquick PCR purification 
kit (Qiagen). qPCR was performed using primers in Table 4.2 and values were calculated 
relative to the input controls. Results represent averages +/- SEM from two experiments. 
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4.2.5 ChIP-seq, RNA-seq and Bioinformatic analysis 
Approximately 10ng of ChIPed DNA and RNA collected from Pygo2 treated 
cells were sent for high throughput sequencing (approximately 50 million reads per 
sample) at Seqwright Genomic Services including some data analysis (GE Healthcare, 
Houston, TX). All other data analyses were performed using SeqMonk v0.33.0 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/), excluding non-unique 
and duplicate reads and mapping them to the reference human genome (GRCH37). 
Briefly, for the ChIP-seq analysis, significant peaks (p < 10
-5
) were called from mapped 
reads with Seqmonk running a version of the MACS peak caller using default parameters. 
Data sets were generated with Pygo2 peaks falling within 1000 base pairs relative to TSS, 
the data sets were then used to make heat maps and trend plots of Pygo2 binding relative 
to TSS. For simple RNA-seq analysis, total reads were first normalized between 
treatments and differences were calculated in Seqmonk running R and compared the 
results of both Pygo2 targeting siRNAs to the NTC control siRNA using default 
Seqmonk parameters. Comparative analysis with H3K4me3, p300 and GCN5 was 
performed using Seqmonk with similar parameters as Pygo2 using the ENCODE Hela S3 
ChIP datasets: ENCSR000AOF, ENCSR000ECR and ENCSR000ECV, respectively. 
Gene ontology analysis was performed using The Database for Annotation, Visualization 
and Integrated Discovery (DAVID ) software using the GO FAT option (Huang et al, 
2009).  
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4.3 Results 
4.3.1 Depletion of Pygo2 results in an accumulation of cells in metaphase with 
mitotic chromosome and spindle defects 
Our group previously demonstrated that depletion of Pygo2 in the p53 null 
SKOV-3 epithelial ovarian cancer cell line resulted in growth arrest, independent of 
Wnt/-Catenin (Popadiuk et al, 2006). Growth arrest of the SKOV-3 cells was 
accompanied by an accumulation of cells in the G2/M phase of the cell cycle, which 
could at least be partly explained by a decreased transcription of the 47S rRNA (Andrews 
et al, 2013). Interestingly, similar G2/M accumulations were also obtained in several 
other p53 null cell lines, including the p53 null metastatic prostate cell line PC3 (Figure 
4.1), thereby revealing a possible role for Pygo2 in G2/M phase of the cell cycle.  
Under closer scrutiny, Pygo2 appeared to have a more direct role in mitosis. 
Mitotic profiles of SKOV-3 cells were compared that were treated with two different 
siRNAs targeting Pygo2 (siPy2-1 and siPy2-2; Figure 4.2A and 4.3) along with a non-
targeting siRNA (siNTC) control. Immunofluorescence staining, using antibodies against 
phospho-histone H3 (p-HH3) and -tubulin to mark dividing cells, indicated that Pygo2 
depletion significantly increased the proportion of cells in metaphase (p<0.001) with a 
corresponding decrease of cells in prophase (p<0.001; Figure 4.2B), suggesting that cells 
may be delayed or arrested in metaphase. Moreover, Pygo2-depleted cells displayed 
defects in which the mitotic spindles appeared abnormal yet mitotic chromosomes failed 
to line up at the metaphase plates (Figure 4.2C). The observed defects in Pygo2  
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Figure 4.1. Pygo2 depletion results in accumulation of G2/M in p53 null PC3 cells. 
PC3 cells were treated for 72 hours with non-targeting (siNTC) or Pygo2 (siPygo2) 
siRNAs, cells were then fixed and stained with propidium iodide and the relative DNA 
content was examined using flow cytometry.  
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Figure 4.2. Depletion of Pygo2 results in mitotic defects. (A) Immunoblot showing a 
reduction of Pygo2 protein in SKOV-3 cells that were treated with a non-targeting siRNA 
(siNTC) or two Pygo2 specific siRNAs (siPy2-1 and siPy2-2), -actin was used to as a 
loading control. (B) Pygo2 was depleted from SKOV-3 cells and cells were co-stained 
with -tubulin and phospho-histone H3 (p-HH3) to visualize and score various mitotic 
stages. Pygo2 depleted cells resulted in a significant accumulation of cells in metaphase, 
consistent with a mitotic delay. Representative images of p-HH3 positive cells in each 
phase shown in the lower panel. (C) Confocal images of SKOV-3 cells co-stained with 
-tubulin and p-HH3 from experiments performed in (B) showing chromosome and 
mitotic spindle defects (scale bar=5m). (D) Quantification of observed mitotic defects, 
showing an increase number of defects in Pygo2 depleted SKOV-3 cells. Bar graphs 
represent averages +/- SEM. (**p<0.01, ***p<0.001, NS; not significant)  
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Figure 4.3. Depletion of Pygo2 with siRNA reduces nuclear Pygo2 protein. Confocal 
images of Pygo2 depleted SKOV-3 cells stained with Pygo2 and -tubulin antibodies 
showing a reduction in nuclear Pygo2 levels. Scale bar = 50m.   
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depleted cells were significantly higher as compared to cells treated with the non-
targeting control (Figure 4.2D; p<0.01). Together, these results suggested that Pygo2 
depletion resulted in mitotic spindle/chromosome defects, resulting in an accumulation of 
cells in metaphase. 
4.3.2 Pygo2 is required for spindle-kinetochore recognition and chromosome 
biorientation 
To investigate potential deficiencies in mitotic spindle function, -tubulin 
expression, which is required for proper centrosome formation and spindle microtubule 
nucleation, was examined (Kollman et al, 2011). In Pygo2 depleted cells, -tubulin 
appeared to be largely unaffected compared to the control-treated cells. However, in 
Pygo2 depleted cells the chromosomes appeared to be misaligned with the presumptive 
metaphase plates and the mitotic spindle microtubules appeared to circumnavigate the 
misaligned chromosomes (Figure 4.4).  
To examine the alignment of the chromosomes and spindle microtubules, the 
localization of spindle microtubules was assessed with respect to the centromeres using 
-tubulin and anti-centromere (CREST) antibodies/antiserum (Figure 4.5). Pygo2 
depletion caused spindle related defects in which the centromeres were oriented in a 
parallel manner to the spindle microtubules, suggesting the chromosomes were not being 
efficiently captured by spindle microtubules. Similar results were obtained upon 
examination of the inner kinetochore protein INCENP (Figure 4.6), a component required 
for targeting and function of the CPC, which plays key roles in the capture of the mitotic 
spindle by the kinetochore during mitosis (Carmena et al, 2012). Next, two other CPC  
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Figure 4.4. Depletion of Pygo2 does not appear to affect -tubulin and the 
centrosome. Confocal images of Pygo2 depleted SKOV-3 cells in metaphase stained 
with -tubulin to visualize mitotic spindles and -tubulin to visualize centrosomes, 
showing little change in microtubule nucleation or centrosome localization. The dashed 
line indicates the plane of cell division and the presumptive metaphase plates. Scale bar = 
5m.  
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Figure 4.5. Pygo2 is required for proper spindle-kinetochore alignment in early 
metaphase cells. Confocal images of Pygo2 depleted SKOV-3 cells during early 
metaphase that were co-stained with anti-centromere antisera (CREST) to visualize 
centromeres and -tubulin and -tubulin to visualize the mitotic spindles and spindle 
poles, respectively. The dashed line indicates the plane of cell division and the 
presumptive metaphase plates. Zoomed panels show misalignment of mitotic spindle 
microtubules and the centromeres and kinetochores. Scale bar = 5m.  
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Figure 4.6. Pygo2 is required for spindle alignment with INCENP. Confocal images 
of Pygo2 depleted SKOV-3 cells during early metaphase that were co-stained with -
tubulin and INCENP to visualize the mitotic spindles and kinetochores, respectively. 
Zoomed panels show misalignment of mitotic spindle microtubules and the centromeres 
and kinetochores. The dashed line indicates the plane of cell division and presumptive 
metaphase plates. Scale bar = 5m.  
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components: AurKB (Figure 4.7) and Survivin (Figure 4.8) were examined revealing a 
similar pattern of disorganized chromosomal- associated staining. However, both AurKB 
and Survivin co-localized weakly with INCENP at kinetochores, suggesting that the 
localization of CPC components to kinetochores was not greatly affected by Pygo2 
depletion.  
AurKA plays key roles in cell division, by controlling centrosome formation and 
also kinetochore microtubule attachment (Nikonova et al, 2013; Katayama et al, 2008). 
We found no change in the centrosomal localization of AurKA but a decrease in staining 
intensity as compared to control-treated cells (Figure 4.9). Similar decreases were 
observed with an antibody that recognizes active phosphorylated AurKA (AurKA P-
T288; Figure 4.9), resulting from autophosphorylation of Threonine 288 (Nikonova et al, 
2013). While we could not detect AurKA at kinetochores (Katayama et al, 2008), the 
reduction of AurKA at centrosomes suggests that its overall expression is likely 
decreased and could contribute to the observed changes in chromosome biorientation. 
These results therefore suggested that overall levels of centrosomal AurKA were affected 
by Pygo2 depletion, while there was little effect on subcellular localization or 
autophosphorylation.  
4.3.3 Pygo2 is required for the expression of genes involved in cell division 
mechanics 
Since Pygo2 protein appears to be excluded from mitotic chromatin (Andrews et 
al, 2013) and the expression of at least one candidate, AurKA, appeared to be affected by 
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Figure 4.7. Pygo2 depletion does not affect the association of CPC components 
AurKB with INCENP. Confocal images of Pygo2 depleted SKOV-3 cells showing the 
localization of CPC components AurKB and INCENP. Scale bar = 5m.  
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Figure 4.8. Pygo2 depletion does not affect the association of CPC components 
Survivin with INCENP. Confocal images of Pygo2 depleted SKOV-3 cells showing the 
localization of CPC components AurKB and INCENP. Scale bar = 5m.  
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Figure 4.9. Depletion of Pygo2 leads to decreases levels of AurKA and active AurKA 
at centrosomes. Confocal images of Pygo2 depleted SKOV-3 cells stained with Aurora 
kinase A (AurKA) and activated phosphorylated AurKA (P-T288), showing a decrease in 
overall AurKA and AurKA (P-T288). For comparative purposes to show differences in 
intensities, confocal images were taken with the same exact settings. Scale bars=5m.  
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loss of Pygo2, I hypothesized that it may function as a chromatin effector involved in the 
transcription of genes either directly or indirectly required for mitosis. To this end, 
Pygo2 was depleted from HeLa S3 cells (Figure 4.10A) and massively parallel RNA-
sequencing (RNA-seq) was performed (Seqwright) on extracted RNA to identify mitotic 
candidate genes.  
 Using RNA-seq analysis, I identified a total of 379 mRNAs that significantly 
changed using both Pygo2-targeting siRNAs compared to the control (siNTC; Figure 
4.10B). Out of the 379 mRNAs, 287 were upregulated and 92 were downregulated 
(Figure 4.10C and 4.10D). Gene ontology (GO) analysis was performed on both up- and 
down-regulated genes using DAVID (Huang et al, 2009). GO analysis of upregulated 
genes revealed functional ontologies in primarily cell proliferation and cell adhesion, 
while GO analysis of downregulated genes revealed functional ontologies, with 
significantly high scoring groups related to mitosis and cell cycle (Figure 4.11), 
consistent with our previous results. 
4.3.4 Pygo2 associates with promoter proximal regions adjacent to TSS 
In an attempt to identify direct Pygo2 target genes, the genome wide association 
of Pygo2 with TSS on HeLa S3 chromatin was interrogated using ChIP followed by high 
throughput massively parallel sequencing (ChIP-seq) of chromatin DNA (Seqwright) 
precipitated by two Pygo2 antibodies; one from a commercial source (ABE109, 
Millipore)  and one (S3I4) that was previously generated and characterized in our lab 
(Tzenov et al, 2015). High confidence peaks were calculated using a version of the  
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Figure 4.10. Genome wide analysis of Pygo2 responsive genes. (A) Immunoblot 
analysis using a Pygo2 specific antibody to confirm Pygo2 knockdown in HeLa S3 cells, 
prior to performing RNA-seq. (B) Scatter plot highlighting upregulated and 
downregulated genes from all genes analyzed by RNA-seq. (C and D) Heat maps 
illustrating the relative expression of the 92 downregulated and 287 upregulated genes 
resulting from Pygo2 depletion, respectively.  
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Figure 4.11. Pygo2 responsive genes are associated with genes involved in cell cycle 
and mitosis. DAVID GO analysis of 287 upregulated (upper panel) and 92 
downregulated (lower panel) genes from RNA-seq analysis. Total number of genes in 
each category are in parenthesis. Benjamani-associated p-values represent a measurement 
of false discovery rate.  
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Model-based Analysis for ChIP-seq (MACS) peak caller using a p-value cut-off of 10
-5
. 
This analysis revealed an enrichment of the most robust peaks (lowest p-values) 
approximately 74 base pairs upstream of transcription start sites (TSS)s for both Pygo2 
antibodies used (Figure 4.12A and 4.12B), indicating that Pygo2 binding was enriched 
around TSSs. Motif analysis of the binding sites associated with Pygo2 revealed a 
correlation with sites that are similar to the FOXP1 consensus sequences and  
loosely correlated with sites that resemble Tcfcp2l1 binding sites (Figure 4.12C). GO 
analysis of common ChIP-seq sites using both Pygo2 antibodies revealed functional 
ontologies related to complex assembly, chromatin, transcription, cell cycle and mitosis 
(Figure 4.13). 
Pygo2 is hypothesized to induce euchromatin formation at transcriptionally active 
target genes by recruiting and promoting histone acetyltransferase (HAT) and 
methyltransferase activity (Gu et al, 2012; Andrews et al, 2009; Chen et al, 2010). I 
therefore compared the genome wide enrichment of Pygo2, H3K4me3, p300 and GCN5 
using available ChIP datasets from ENCODE performed on HeLa S3 cells. I found the 
genome-wide association of Pygo2 on chromatin relative to TSS was correlated with the 
position of p300 binding and it also showed a positive correlation with the HAT GCN5 
and active H3K4me3 marks at promoters (Figure 4.14). 
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Figure 4.12. Genome wide analysis of Pygo2 enrichment with chromatin. Probe trend plots 
(A) and aligned probe plots (B) generated from HeLa S3 ChIP-seq data using two different Pygo2 
antibodies (Abe109 and S3I4) indicating the average enrichment of Pygo2 from -2000 to +2000 
relative to transcriptional start sites (TSS), with the maximum enrichment occurring 
approximately 74 bp upstream of TSS. (C) Peak motif analysis of Pygo2 peaks revealing between 
30-50 FOXP1 binding sites (motif 1; upper panel) and between 7-9 Tcfcp2l1 binding sites (motif 
2; lower panel).  
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Figure 4.13. DAVID GO analysis of the common 1341 ChIP-seq genes using two 
different Pygo2 antibodies. The total number of genes in each category is in parenthesis. 
Benjamani-associated p-values represent a measurement of false discovery rate.   
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Figure 4.14. Pygo2 enrichment at TSS correlates with H3K4me3 and HATs. Probe 
trend plots showing correlation of enriched Pygo2 binding (Abe109) with the active 
histone mark H3K4me3 and the HATs p300 and GCN5, with respect to TSS in HeLa S3 
cells. 
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4.3.5 Pygo2 directly regulates a subset of genes involved in mitotic cell division 
control 
To reduce false positives and identify bona fide functional Pygo2 target genes I 
examined 1341 genes that showed enriched Pygo2 binding common to both Pygo2 
antibodies used in the ChIP-seq analysis. To expand our downregulated gene list to all 
functionally downregulated Pygo2 target genes, I compared the relative expression of the 
1341 genes with those analyzed by RNA-seq and found that 210 of the 1341 genes 
showed a reduction in RNA expression to less than 75 percent with two Pygo2-targeting 
siRNAs compared to the non-targeting control (Figure 4.15A).  
Among the 210 genes were several histone gene targets that were previously 
identified to be directly regulated by Pygo2 (Gu et al, 2012), providing independent 
validation of my ChIP-seq and RNA-seq analysis (Figure 4.16; p<0.001). While not 
direct Pygo2 target genes, I observed an increase in p21 expression (p<0.01), consistent 
with previous results (Gu et al, 2009; Andrews et al, 2013) and a concomitant decrease in 
the proliferation marker KI-67 (Figure 4.16; p<0.001). Gene ontology (GO) analysis was 
performed on the 210 identified Pygo2 target genes using DAVID (Huang et al, 2009). 
This analysis revealed a significant association of GOs related to mitotic cell division and 
spindle assembly (Figure 4.15B), which correlated with the independent RNA-seq and 
ChIP-seq analysis. 
 To confirm expression of the subset of genes identified by RNA-seq with GOs 
related to mitotic cell division, I performed RT-qPCR analysis for 15 candidate genes,  
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Figure 4.15. Pygo2 is directly involved in controlling the transcription of a subset of 
genes involved in mitotic cell division. (A) Workflow of whole genome analysis using 
ChIP-seq and RNA-seq to identify 210 functionally relevant Pygo2 target genes. 
Expression of 1341 common genes that showed Pygo2 enrichment within 1000bp of TSS 
using two Pygo2 antibodies was analyzed by RNA-seq data of HeLa S3 cells that were 
treated with two Pygo2 targeting siRNAs, compared to a non-targeting siRNA control. 
210 of 1341 genes whose expression were downregulated lower than 75 percent 
compared to the control were identified. (B) Top functional GO categories using DAVID 
software to analyze the 210 genes identified by ChIP-seq and RNA-seq (parenthesis 
indicate number of associated genes in each category). (C) Depletion of Pygo2 in HeLa 
S3 cells followed by RT-qPCR to examine and validate the RNA expression of Pygo2 
and 15 candidate Pygo2 target genes with ascribed function in cell division. Reduced 
expression of all genes, p<0.001.  
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Figure 4.16. Pygo2 is required for histone and cell cycle gene expression. RT-qPCR 
of histone genes (H4E and H4B), p21 and proliferation marker KI-67 normalized to -
actin expression in Pygo2 depleted HeLa S3 cells. Bar graphs represent mean +/- SEM. 
(***p<0.001, **p<0.01)  
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which showed function in mitotic spindle-kinetochore assembly, following Pygo2 
depletion (Figure 4.15C). Depletion of Pygo2 resulted in a significant reduction to less 
than 50 percent compared to that of the controls for all the mitotic candidate genes 
analyzed (p<0.001). Interestingly, among these were genes directly required for 
microtubule attachment to the kinetochores, such as RCC1, INCENP, AurKA and TPX2, 
consistent with the mitotic defects observed (Figure 4.2). 
4.3.6 Pygo2 plays a role in H3K27Ac at genes required for mitosis 
To assess whether Pygo2 plays a role in euchromatin formation at mitotic target 
genes, the status of H3K4 trimethylation and H3K9, K14 and K27 acetylation was 
examined at the promoters of five randomly chosen target genes identified from Figure 
4.15C (Figure 4.17). As a control, depletion of Pygo2 resulted in a reduction of Pygo2 
bound to the promoters of all genes analyzed (p<0.05). While not statistically significant 
(p>0.05/p=NS), Pygo2 depletion resulted in an observed decrease of both H3K9 
acetylation and H3K4 trimethylation compared to the control treated cells at the BOD1, 
RCC1 and INCENP promoters, consistent with a role for Pygo2 in functionally binding to 
MLL2 and GCN5 (Chen et al, 2010). While there was no observed difference in H3K14 
acetylation (p=NS), Pygo2 depletion on the other hand, resulted in decreased H3K27 
acetylation at all the promoters analyzed (p<0.05), consistent with a required role in their 
expression (Figure 4.15C), highlighting the role of Pygo2 as a chromatin effector. 
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Figure 4.17. Pygo2 plays a role in H3K27Ac at gene promoters involved in the 
regulation of mitosis. Examination of the relative enrichment of Pygo2, H3K4me3, 
H3K9Ac, H3K14Ac and H3K27Ac in Pygo2 depleted HeLa S3 cells, at the BOD1, 
RCC1, INCENP, CEP290 and AurKA promoter regions by ChIP-qPCR. Bar graphs 
represent averages +/- SEM. (*p<0.05, NS; not significant)  
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4.3.7 Association between Pygo2 and the c-myc proto-oncogene 
The foregoing results suggested an essential role for Pygo2 in promoting a 
transcriptional program required for cell division. Interestingly, some of the critical 
Pygo2 target genes identified, such as AurKA and RCC1, were also targets of the c-myc  
proto-oncogene (Den Hollander et al, 2010; Tsuneoka et al, 1997). This prompted the 
hypothesis that Pygo2 and c-myc may be present in a complex and may regulate similar  
sets of genes. Therefore, ChIP-seq public-domain (ENCODE) data for c-myc binding in 
HeLa S3 cells were compared with the data obtained for Pygo2 to ascertain an in silico 
association. Strikingly, I found that approximately 50% of the identified Pygo2  
ChIP-seq and functional target genes were also occupied by c-myc (Figure 4.18A), 
thereby suggesting the proteins may target similar sets of genes. Analysis of the 117 
functional Pygo2 and c-myc genes revealed ontologies mainly related to mitotic cell 
division (Figure 4.18B)  
Interestingly, the accumulating evidence for Pygo2 in malignant growth parallels 
the oncogenic potential of c-myc. For example, the growth promoting activity of c-myc, 
and as we have shown for Pygo2, partly depends on its requirement for rDNA gene 
expression (Grandori et al, 2005; Arabi et al, 2005). Therefore, to test the existence of a 
Pygo2/c-myc interaction, both Pygo2 and myc tagged (MT) c-myc were co-transfected 
into HEK-293 cells and forward and reverse immunoprecipitations were performed and 
confirmed an interaction between the two proteins (Figure 4.19A). The interaction 
between Pygo2 and c-myc was confirmed in HeLa S3 cells using Pygo2 antisera to 
immunoprecipitate Pygo2 and by performing immunoblots for c-myc (Figure 4.19B). 
Finally, Pygo2 and c-myc showed a similar pattern of localization in the nuclei of HeLa  
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Figure 4.18. In silico analysis of Pygo2/c-myc (MYC) genes in HeLa S3 cells. (A) Left 
panels represent Pygo2 target genes and functional Pygo2 target genes that were 
identified in Figure 4.15. Right panels show the association of the Pygo2 target genes that 
are shared with c-myc. (B) Gene ontologies associated with 117 “functional” Pygo2/c-
myc genes.  
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Figure 4.19. In vivo association between Pygo2 and c-myc. (A) Pygo2 and c-myc 
interact in HEK-293 cells that were co-transfected and immunoprecipitated (IP) with 
MT-myc and Pygo2. Immunoblots (IB) were performed with myc and Pygo2 antibodies. 
(B) Pygo2 and c-myc interact in HeLa S3 cells. Cells were co-transfected with Pygo2 and 
c-myc, immunoprecipitations were performed with either pre-immune sera or Pygo2 
antisera.  
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Figure 4.20. Pygo2 and c-myc co-localize in the nuclei of HeLa S3 cells. (A) Confocal 
images of cells that were co-transfected with different combinations of GFP, GFP-Pygo2 
(GFP-Py2), MT and MT-myc, cells were stained with antibodies recognizing MT and 
DAPI to visualize nuclei. Scale bar = 10m. (B) Pygo2 and c-myc co-localize in the 
nucleus of DMSO and MG132 treated HeLa S3 cells. Arrows indicate co-localization in 
presumptive nucleoli. Scale bar = 5m.  
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S3 cells that were co-transfected with green fluorescent protein (GFP) tagged Pygo2 and 
MT-myc (Figure 4.20A). 
The c-myc protein is rapidly turned over by proteasomal degradation, resulting in 
a relatively short half-life. Nucleolar localization of c-myc was observed in cells 
expressing elevated levels of c-myc or when proteasome inhibitors were used to increase 
its expression (Arabi et al, 2003). In HeLa S3 cells both endogenous c-myc and Pygo2  
appear to localize mainly to the nucleoplasm and chromatin, with punctate co-localization 
in the nucleoli in untreated or vehicle treated (DMSO) cells (Figure 4.20B).  
These results suggested that in addition to the Pygo2/c-myc target genes outlined 
above, Pygo2/c-myc containing complexes may also play a role in ribosomal RNA 
transcription. Upon treatment of cells with the proteasome inhibitor MG132, there was an 
increased co-localization of both Pygo2 and c-myc to the presumptive nucleolar regions 
of the nuclei of HeLa S3 cells (Figure 4.20B), thereby suggesting the possibility of 
Pygo2/c-myc complexes in ribosomal RNA transcription, consistent with previous 
findings (Andrews et al, 2013; Grandori et al, 2005; Arabi et al, 2005).  
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4.4 Discussion 
Here, my findings suggest that the chromatin effector Pygo2 controls a 
transcriptional program required for mitosis. Consistently, Pygo2 was required to 
maintain levels of H3K27 acetylation at promoters and expression of genes involved in 
microtubule-kinetochore interactions facilitating chromosome biorientation (Figure 4.21). 
Pygo2 was also associated with H3K4 trimethylation at select promoters (Figure 4.17), 
consistent with a role for Pygo2 in promoting H3K4me3 through a histone 
methyltransferase dependent mechanism (Chen et al, 2010). Examination of functional 
genome-wide Pygo2 binding sites revealed that more than half of the promoters occupied 
by Pygo2 were also occupied by the proto-oncogene c-myc. Finally, identification of a 
novel interaction between Pygo2 and c-myc, thereby suggests the existence of a Pygo2/c-
myc dependent transcriptional program that is involved in cell division control. 
My results suggest at least one possible explanation for the observed chromosome 
segregation defects is dependent on a transcriptional program regulated by Pygo2. During 
mitosis, Pygo2 appears to dissociate from the condensed mitotic chromatin (Andrews et 
al, 2013), however it is possible that Pygo2 may also play a direct role in kinetochore 
organization. Centromeric chromatin is unique, composed of repetitive -satellite DNA 
which is recognized and organized by the histone H3 variant, Centromere Protein A 
(CENP-A; Ohzeki & Larionov, 2015). Using human artificial chromosomes, it was 
demonstrated that CENP-A assembly is dependent on acetylation by PCAF or p300 
(Ohzeki et al, 2012). Since Pygo2 is associated with PCAF and p300 HATs (Chen et al, 
2010; Andrews et al, 2009; Andrews & Kao, 2016), raising the possibility that 
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Figure 4.21. Proposed mechanism of the transcriptional control of cell division by 
Pygo2. Complexes of Pygo2 and c-myc may be required for the recruitment of HATs to 
genes involved in cell division required for H3K27 acetylation and normal kinetochore 
capture by spindle microtubules (top panel). Depletion of Pygo2 results in lower amounts 
of H3K27 acetylation causing a reduction in expression of genes involved in cell 
division, resulting in aberrant capture of kinetochores by spindle microtubules.  
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Pygo2 may be involved in centromere assembly by promoting CENP-A acetylation.    
Little change was observed in the centrosomes and mitotic microtubules in Pygo2 
depleted cells (Figure 4.4), indicating proper centrosome function and bipolar spindle 
assembly. Further examination revealed defects in in spindle-kinetochore recognition 
(Figure 4.5 and 4.6), similar to chromosome alignment defects in cells deficient in a 
kinetochore protein known as biorientation of chromosomes in division 1 (BOD1), 
required for the detection of syntelic attachments by the mitotic spindle (Porter et al, 
2007).  
Additionally, we identified Regulator of Chromosome Condensation 1 (RCC1) as 
a direct Pygo2 responsive gene and Pygo2-dependent spindle defects resemble spindle 
defects resulting from overexpression of a dominant negative RCC1 (Moore et al, 2002). 
Kinetochore associated RCC1 required for the binding of GTP to Ras-related nuclear 
protein (RanGTP), is necessary to form a concentration gradient of RanGTP, required for 
kinetochore proximal microtubule nucleation and kinetochore recognition (Kalab & 
Heald, 2008). While not explored here, the Pygo2 dependent reduction of RCC1 
expression may also reduce the gradient of RanGTP, thereby affecting spindle-
kinetochore interaction.  
Depletion of Pygo2 resulted in the reduction in expression of TPX2 and AurKA. 
Both of which are involved in the formation of kinetochore-derived microtubule 
nucleation that aids in spindle-kinetochore interactions (Katayama et al, 2008). While 
AurKA could not be detected at kinetochores, the general reduction of AurKA and 
activated phospho-AurKA at centrosomes suggests a reduction of active AurKA at 
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kinetochores is likely. Overall, these results suggest that Pygo2 plays a role in the 
expression of key genes involved in directing mitotic spindle-kinetochore interaction. 
It is already well established that Pygo binds directly to H3K4me3 (Fiedler et al, 
2008). In stride with this, on a global scale with respect to TSS, Pygo2 preferably binds 
to proximal promoter regions, which strongly correlated with H3K4me3 enrichment 
(Figure 4.14).  In malignant and transformed cells Pygo2-H3K4me3 binding is important 
for cell growth and expansion (Gu et al, 2009), but a recent study revealed that Pygo2 
binding to H3K4me3 through its PHD motif was dispensable for normal development 
and target gene transcription (Cantù et al, 2013). Here, I hypothesize that Pygo2 is likely 
targeted to active gene promoters through a mechanism that could be either directly or 
indirectly through H3K4me3 marks, as evidenced by the strong correlation with HAT 
enrichment (Figure 4.14).  
The canonical binding of c-myc to specific E-box enhancer elements on DNA, 
which lie upstream of TSS, occurs in cooperation with its partner MAX. However, the 
genome wide association of c-myc with DNA revealed that it was strongly associated at 
active TSS lacking canonical E-box motifs, thereby suggesting that c-myc may be 
targeted to active promoters, independent of MAX (Kress et al, 2015). While the 
association between Pygo2 and MAX is unknown, its association with c-myc offers the 
interesting possibility that Pygo2 may be involved in recruiting c-myc to active promoters 
through the direct binding to H3K4me3 marks to activate specific transcriptional 
programs including cell division and ribosome production. It is also possible that 
Pygo2/c-myc could be targeted by other promoter bound factors to promote histone 
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acetylation (Figure 4.12C), such as the oncogene FOXP1 (Fox et al, 2004; Choi et al, 
2015).  
The interaction between c-myc and Pygo2 raises the possibility of an interaction 
between Pygo2 and other myc family members, such as n-myc, which has been shown to 
play roles in both normal development and cancer. In normal development, n-myc 
expression is restricted to certain developing tissues, such as neural progenitor cells, hair 
follicles, retinas and lenses (Hirning et al, 1991), closely mirroring the expression and 
function of Pygo2 in normal development. Furthermore, n-myc can functionally 
substitute for c-myc during normal development (Malynn et al, 2000) and has been 
associated with a variety of cancers, such as neuroblastoma (Westermark et al, 2011). 
These observations suggest the interesting possibility that Pygo2 and n-myc complexes 
could play important roles in both normal development and cancer.  
Its documented overexpression and requirement for growth suggests that Pygo2 is 
an important biomarker and possible therapeutic target in a number of different cancers 
(Liu et al, 2013; Andrews et al, 2007; Watanabe et al, 2013; Popadiuk et al, 2006; 
Andrews et al, 2008; Gu et al, 2012; Zhang et al, 2015a; Andrews et al, 2013; Tzenov et 
al, 2013; Yang et al, 2013; Sun et al, 2014; Zhang et al, 2015b; Zhou et al, 2014; Li et al, 
2015).  Furthermore, Pygo2 plays key roles in cell growth by facilitating euchromatin 
formation at genes required for both nucleosome and ribosome biogenesis (Gu et al, 
2012; Andrews et al, 2013). While these processes clearly link Pygo2 function to the 
demands of a growing cell, these results demonstrate that the chromatin modulator Pygo2 
is similarly involved in a transcriptional program essential for mitotic cell division, 
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suggesting that Pygo2 function may be important to coordinate cell growth with mitotic 
division.  
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Chapter 5: Summary  
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5.1 Pygo2 as a permissive Wnt chromatin effector in cancer 
Over the past few decades there has been mounting evidence highlighting the 
importance of chromatin remodeling events that drive proliferative growth. In this thesis, 
I presented Pygo2 as an emerging player in the epigenetic control of cell growth and 
division, thereby identifying Pygo2 as an important therapeutic target in cancer. I 
hypothesized that Pygo2 acts as an adapter or “docking” protein required for HAT 
binding and euchromatin formation at active gene promoters driving cancer cell growth 
and division. Pygo2 is targeted to active gene promoters primarily through H3K4me3 
marks, however, more complex interactions with transcription factors at both gene 
enhancers and/or promoters are conceivably required to dictate the sets of genes that get 
turned on. For example, the interaction of Pygo2 with complexes containing Bcl9/-
catenin (Chapter 2) or with UBF/Treacle (Chapter 3) likely dictates its chromatin effector 
function in either Wnt signalling or ribosomal RNA transcription, respectively. However, 
the interaction of Pygo2 with c-myc only partially explains its requirement in 
transcription of genes involved in mitosis, since approximately half of the Pygo2 
enriched genes showed a co-enrichment for c-myc (Figure 4.18), indicating that Pygo2 
may also co-operate with other unknown transcriptional complexes to fulfil its role in 
transcription and chromatin remodeling.  
Pygo2 is expressed in almost all developing tissues and evidence from Pygo2 null 
mice support the idea that it may be relevant in all cells to promote proliferation. Pygo2 is 
clearly required to promote the development of certain tissues such as the lens and kidney 
(Song et al, 2007; Schwab et al, 2007). In addition, Pygo2-null fetuses are significantly 
smaller than wild-type littermates (Li et al, 2007a; Schwab et al, 2007; Song et al, 2007), 
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suggesting that it may be important for development of many different tissues. Pygo2 is 
also expressed in normal human cells, albeit at lower levels compared to immortalized 
and malignant cells (Popadiuk et al, 2006; Andrews et al, 2007; Tzenov et al, 2013). 
Collectively, these data suggest that Pygo2 function may be important to promote 
the growth of normal cell types, consistent with a model of cell growth and division 
regulation by Pygo2 (Figure 5.1). Here, cell growth and division driven by Wnt 
signalling, for example, results in the recruitment of the active -catenin transcriptional 
complexes to target genes, such as cyclin D1 and c-myc. Transcriptional activation 
requires HAT recruitment by the Pygo2/-catenin complex to promote necessary 
euchromatic changes necessary for transcriptional initiation. In the active -catenin 
complex, Pygo2 becomes acetylated, which likely occurs concurrently with histone 
acetylation and promotes the dissociation of active complexes (Chapter 2).  
Cyclin D1 is required for phosphorylation of the Retinoblastoma (Rb) protein and 
cell cycle progression though the G1/S checkpoint of the cell cycle. Inactivation of Rb by 
phosphorylation activates a transcriptional program, primarily mediated by the activation 
of E2F (Dick & Rubin, 2013; Ren et al, 2002) and Elf-1 (Wang et al, 1993), resulting in 
an increase in Pygo2 expression (Tzenov et al, 2013; Andrews et al, 2008). I hypothesize 
that the increase in c-myc and Pygo2 expression results in the activation of gene 
expression program(s) promoting cell growth and biomass accumulation through both 
histone (Gu et al, 2012) and ribosome production (Chapter 3; Andrews et al., 2013). It is 
possible that this activity is coupled to a consequent or subsequent activation of cell 
division machinery by Pygo2/c-myc complexes (Chapter 4). Therefore, the chromatin  
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Figure 5.1. Proposed model of normal and aberrant growth regulation by the 
chromatin effector Pygo2. (For description see text in section 5.1)  
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remodelling function of Pygo2 may be required in multiple contexts, in an overall theme 
of promoting cell growth and division.  
 In normal cells the function of Pygo2 as a general effector of cell expansion 
would require careful regulation and at each cell cycle, newly minted daughter cells 
would be competent to respond to additional waves of growth promoting Wnt signals. I   
speculate that if this proposed function were abnormally hyper-stimulated in normal cells, 
feedback tumor suppressor programs would become activated to attenuate 
the growth response, similar to the p14ARF dependent activation of p53 by mitogenic c-
myc activation (Zindy et al, 1998).  
In cancer, it is likely that Pygo2 activity is hijacked during tumorigenesis and 
takes on a role as an oncogenic accessory protein, promoting open chromatin structure to 
facilitate gene expression, an idea worthy of further discussion. The probable functional 
interaction between Pygo2 and c-myc offers a convenient avenue addressing this 
interesting possibility. Importantly, the myc genes and proteins lie downstream of many 
pro-growth related signaling pathways and act as master regulators of the growth 
response (Dang, 2012; Califano & Alvarez, 2016). The overall outcome of aberrant myc 
expression results in transcriptional amplification necessary to drive cancer cell growth 
(Nie et al, 2012; Lin et al, 2012). To date, there is no evidence suggesting Pygo2 alone 
plays a role in cellular transformation, suggesting that its role in tumorigenesis could be 
dependent on c-myc. The involvement of Pygo2 in growth and division related 
transcriptional programs parallels the requirement of c-myc in promoting cell 
proliferation related to cancer (Dang, 2012). I therefore hypothesize that Pygo2 and c-
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myc constitutes a functional unit required for cell proliferation, whether c-myc hijacks 
Pygo2 or vice versa, remains to be determined. 
Cancer cells, whose uncontrolled growth phenotypes are partly dependent on the 
loss of tumor suppressors, bypass the G1/S phase checkpoint and undergo continuous 
growth (Figure 5.1; “deregulated”). Here, aberrant growth signalling cascades converge 
and result in the over expression of c-myc as well as additional proto-oncogenes and 
master regulators to supercharge cell proliferation. Moreover, the coupled inactivation of 
Rb results in the overexpression of Pygo2 at the mRNA and protein levels. I propose that 
the deregulated expression of both c-myc and Pygo2 and their cooperative roles in 
promoting aberrant gene expression increases cellular capacity to both grow and divide, 
likely through the recruitment of chromatin remodelling machinery.   
5.2 The chromatin effector Pygo2 as a druggable molecule in cancer. 
 It is not surprising that targeting chromatin-remodeling proteins in cancer has 
garnered much recent attention. For example, inhibition of c-myc gene expression has 
been achieved in a number of cancers with the small molecule inhibitor JQ1, which binds 
and inhibits the epigenetic function of the bromodomain-containing protein Brd4 
(Filippakopoulos et al, 2010). Recently, there have been attempts to target Pygo2 with 
small molecules that bind to the PHD motif disrupting its interaction with H3K4me3 and 
Bcl9 (Miller et al, 2014; Ali et al, 2016). Moreover, the small molecule targeting Pygo2 
called JBC117, identified by Ali and coworkers was shown to display anti-cancer 
properties in both colorectal and lung cancer cells (Ali et al, 2016). Since the PHD 
domain of Pygo2 is largely dispensable for normal development (Cantù et al, 2013), 
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while it appears to be important for cancer growth (Ali et al, 2016), targeting the Pygo2 
PHD finger in cancer may be therapeutically feasible with reduced side effects in normal 
cells. Furthermore, there are several studies that provide direct evidence for the 
requirement of Pygo2 in tumor formation and its association with disease progression and 
clinical outcome (Watanabe et al, 2013; Zhang et al, 2015a), bolstering Pygo2 as a 
potential therapeutic target. However, since Pygo2 functions in adult stem cell 
maintenance, further studies are needed to assess the efficacy of targeting the Pygo2 PHD 
domain.  
Although the crystal structure of the full Pygo2 protein or the NHD remains to be 
solved, targeting the NHD with a small molecule inhibitor may also prove to be useful. 
The NHD region of Pygo family members is highly conserved and shares little homology 
with other proteins, therefore making it an attractive region for small molecule targeting. 
Thus far, the Pygo2 NHD appears to be required for the transcriptional activity of Pygo2, 
by mediating the binding of HATs, HMTs, H3K4me3 and the mediator complex 
(Andrews et al, 2009; Chen et al, 2010; Carrera et al, 2008). While the exact amino acid 
sequences that mediate Pygo2 binding to the abovementioned proteins is unknown, our 
group and others (Andrews et al, 2009; Chen et al, 2010; Andrews et al, 2013) have 
identified a short sequence comprising the first 47 amino acids within the NHD region of 
Pygo2 likely constitutes a multi-protein-protein interaction interface. Therefore, future 
studies will be needed to analyze the structure and the binding of this functional unit to 
HATs and HMTs.  
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5.3 Future endeavors 
 I believe that I made my most interesting observations toward the end of this 
thesis, regarding the existence of a Pygo2/c-myc complex that may control gene 
expression. Preliminary studies in both cultured cervical and prostate cells suggest that 
there is a positive correlation between the number of Pygo2/c-myc complexes present in 
cancer cells compared to “normal” primary cells. These results suggest that Pygo2 and c-
myc may indeed be linked to the cancer phenotype and this interaction may be of clinical 
value in cancer diagnostics. Since both Pygo2 and c-myc likely converge on target genes 
involved in cell growth and division, future work regarding a functional Pygo2/c-myc 
interaction may represent an important perspective for targeted cancer therapies.  
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